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Amos B. Smith, III 
 
The dissertation herein presents the first total synthesis of (–)-irciniastatin B in 
conjunction with the design and synthesis of analogues. Chapter One details the isolation 
and biological data of two potent cytotoxins (+)-irciniastatin A and (–)-irciniastatin B by 
Pettit and Crews. Also outlined in Chapter One are selected total syntheses and endgame 
strategies for (+)-irciniastatin A and reported structure activity relationship studies of the 
irciniastatin family of natural products.  
The synthetic strategy toward the construction of (–)-irciniastatin B is outlined in 
Chapter Two. A chemoselective deprotection/oxidation sequence was proposed to install 
the requisite oxidation state at C(11). To this end, a late-stage alcohol from the earlier 
Smith synthesis of (+)-irciniastatin A was employed. However, protection of the late-
stage alcohol as an orthogonal SEM ether resulted in unexpected degradation. A modified 
protecting group strategy employing robust 3,4-dimethoxybenzyl ethers successfully led 
to the first total synthesis of (–)-irciniastatin B. This strategy also led to the construction 
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of (+)-irciniastatin A from (–)-irciniastatin B, confirming the structural relationship of 
these two secondary metabolites. 
The design and synthesis of irciniastatin analogues are detailed in Chapter Three. 
Our synthetic strategy permits modification at C(11), which has been suggested to be a 
key structural element for the potent biological activity observed with the irciniastatins. 
Biological evaluation of C(11)-irciniastatin analogues will aid in the elucidation of the 
biological mode of action of the irciniastatin family of natural products. 
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CHAPTER 1 Introduction 
Adapted with permission from An, C.; Jurica, J. A.; Walsh, S. P.; Hoye, T. A.; Smith, A. 
B. III. “Total Synthesis of (+)-Irciniastatin A (a.k.a Psymberin) and (–)-Irciniastatin B” 
Journal of Organic Chemistry. 2013, 78, 4278-4296. Copyright 2013 American Chemical 
Society. 
1.1 Introduction: Irciniastatin Family 
In 2004 two new potent cytotoxins, (+)-irciniastatin A (1.1) and (–)-irciniastatin B 
(1.2), isolated from the Indo-Pacific marine sponge Ircinia ramosa, were reported by 
Pettit and coworkers (Figure 1.1).1 In the same year, a closely related metabolite, (+)-
psymberin (1.1), was reported independently by Crews and coworkers from marine 
sponge Psammocinia.2 Analysis of these reports suggests that irciniastatin A (1.1), 
irciniastatin B (1.2), and psymberin (1.1) possessed the same architectural features, 
including a highly substituted 2,6-trans-tetrahydropyran core, a dihydroisocoumarin, and 
an N,O-aminal.  
Figure 1.1. Irciniastatin Family 
 
 
 
The molecular structures of these natural products are very similar to the members 
of the pederin family of natural products (Figure 1.2). Pederin was first isolated in 19523 
and fully characterized in 1965.4 Currently, there are 36 known members of this family of 
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natural products, including pederin (1.3),3 theopederin B (1.4),5 and mycalamide A (1.5).6 
Similar to the irciniastatins, all members of this family possess potent protein synthesis 
and tumor growth inhibition properties.7 In each case, they possess a similar trans-
tetrahydropyran core and an acid-labile N,O-aminal group. Instead of an acyclic acid side 
chain that is present in the irciniastatins, the members of the pederin family have a cyclic 
psymberate side chain. The most notable difference is the absence of the 
dihydroisocoumarin group. Due to their similarities, many structure activity relationship 
(SAR) studies and biological evaluations were driven by the hypothesis that these two 
families of natural products possess similar biological mode of actions.  
Figure 1.2. Pederin Family 
 
 
 
 
 
1.1.1 Characterization of (+)-Irciniastatin A and (–)-Irciniastatin B by the Pettit 
Laboratory 
 The Pettit laboratory1 characterized (+)-irciniastatin A and (–)-irciniastatin B by 
employing high-resolution mass spectrometry and 2-D NMR techniques. The high-
resolution FAB mass spectrum of (+)-irciniastatin A revealed a pseudomolecular ion 
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peak at m/z 610.3228 [M+H]+, which led to a molecular formula of C31H48NO11. The 
combined 1-D and 2-D NMR spectral data permitted structure assignment of (+)-
irciniastatin A as 1.6 (Figure 1.3). The relative stereochemical configurations at C(3)-
C(4) and C(15)-C(16) however remained undefined. Interestingly, the assigned (R) 
configuration at C(8) is the opposite configuration as that in the pederin family of natural 
products. 
Figure 1.3. Structural Determination of (+)-Irciniastatin A (1.6) and (–)-Irciniastatin B 
(1.7) by Pettit and Coworkers 
 
  
 
Pettit et al. determined the molecular formula for (–)-irciniastatin B (1.7), via 
high-resolution FAB mass spectroscopy to be C31H45NO11. Compared to (+)-irciniastatin 
A (1.6), the 13C NMR revealed the absence of a hydroxyl group and the appearance of a 
ketone signal. HMBC correlations and 13C NMR data indicated that the carbonyl resides 
at C(11); thus the two cytotoxins differ only at the oxidation state at C(11) (Figure 1.3).   
1.1.2 Characterization of (+)-Psymberin by the Crews Laboratory 
 The molecular ion of (+)-psymberin2 was characterized via ESI-MS/MS analysis 
of the m/z 610 ion that fragmented to give m/z 578 and 560. A negative ESIMS ion was 
observed at m/z 608 [M–H]–. The molecular formula of psymberin was therefore assigned 
as C31H47NO11. Combination of 2-D NMR studies revealed the structure of psymberin to 
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1.8 (Figure 1.4). The absolute stereoconfiguration at C(4) remained undefined, while the 
C(8) N,O-aminal stereocenter was assigned as (S), which is opposite of that reported by 
Pettit,1 but identical to the pederin family of natural products. Importantly, the C(8)-(S) 
configuration in the pederins proved to be highly important for potent cytotoxicity.8,9 
Crews also determined the relative stereochemical configuration of the C(15)-C(17) 
stereo-triad via NOESY and HSQMBC analysis of coupling constants, which provided 
additional stereochemical information for the initial analysis by Pettit.1 
Figure 1.4. Structural Determination of (+)-Psymberin (1.8) by Crews and Coworkers 
 
 
 
Crews postulated that both (+)-irciniastatin A (1.6) and (+)-psymberin (1.8) might 
be identical,2 but unfortunately the NMR spectra of the two congeners were taken in 
different solvents, thus the exact stereochemical relationship at C(4) and C(8) could not 
be established. In 2005, De Brabander and colleagues resolved the structural ambiguity 
with the first total synthesis of (+)-psymberin by construction of all four C(4)-C(8) 
diastereomers of (+)-psymberin.10 This effort not only yielded the absolute configuration 
of (+)-psymberin (1.1) (Figure 1.1), but also confirmed that both (+)-irciniastatin A (1.1) 
and (+)-psymberin (1.1) possessed identical chemical structures.10 In this thesis, we will 
use the names irciniastatin A and B as Pettit was the first to report these natural 
products.1 
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1.2 Biological Evaluation of (+)-Irciniastatin A (1.1) and (–)-Irciniastatin B (1.2) 
1.2.1 Pettit’s Biological Studies 
Pettit and coworkers tested both (+)-irciniastatin A (1.1) and (–)-irciniastatin B 
(1.2) against a series of human cancer cell lines and murine P388 leukemia cell line.1 
They discovered both natural products displayed impressive biological properties (Table 
1.1). Interestingly, even though the chemical structures of (+)-irciniastatin A (1.1) and    
(–)-irciniastatin B (1.2) differ only in the oxidation state at C(11), the ketone congener 
(1.2) was nearly 10 times more active than the alcohol congener (1.1) against human 
pancreas (BXPC-3), breast (MCF-7), and central nervous system (SF268) cancer cell 
lines.1 This significant difference in activity suggested that the C(11) substituent plays an 
important role in the biological mode of action. Additionally, (+)-ircinaistatin A (1.1) 
possesed modest antifungal and antibacterial activities against Cryptococcus neoformans 
and Neisseria gonorrhoeae (16 µg/mL and 64 µg/mL respectively). 
Table 1.1. Inhibition of Cancer Cell Line Growth (GI50Table, µg/mL) by (+)-Irciniastatin 
A (1.1) and (–)-Irciniastatin B (1.2) 
 
 
 
 
Human cancer cell lines irciniastatin A irciniastatin B
pancreas BXPC-3 0.0038 0.00073
breast MCF-7 0.0032 0.00050
CNS SF268 0.0034 0.00066
lung NCI-H460 <0.0001 0.0012
colon KM20L2 0.0027 0.0021
prostate DU-145 0.0024 0.0016
leukemiaa 0.00413 0.006P388
normal endothelial <0.005HUVEC ND
aMurine.
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1.2.2 Crews’ Biological Studies 
Crews and coworkers evaluated (+)-irciniastatin A (1.1) against the NCI 60 
human tumor cell panel (Table 1.2).2 Interestingly, (+)-irciniastatin A (1.1) displayed 
highly differential cytotoxicity (>10,000-fold). Irciniastatin A [(+)-1.1] possessed high 
sensitivity toward several melanoma, breast cancer, and colon cancer cell lines, while 
leukemia cell lines tested proved to be insensitive, when treated with the cytotoxin. 
Significantly, this differential biological profile was unprecedented in the pederins, which 
raised an intriguing possibility that the observed cytotoxicity of the irciniastatins might 
arise via a novel mode of action. 
Table 1.2. Differential Sensitivities (LC50) of Different Cancer Cell lines to (+)-
Irciniastatin A (1.1) 
 
 
 
 
1.2.3 Usui’s Biological Studies 
In 2010, Usui and coworkers probed the biological mechanism of (+)-irciniastatin 
A (1.1) after completion of a total synthesis.11,12 They determined (+)-irciniastatin A (1.1) 
was a potent protein translation inhibitor (IC50 = 6.7 nM) without affecting DNA and 
RNA syntheses in human leukemia Jurkat cells. Similar results were obtained when (+)-
irciniastatin A (1.1) was evaluated against human cervical carcinoma HeLa cells (IC50 = 
Cancer cell lines LC50 (nM)
leukemia
CCRF-CEM > 25,000
HL-60 (TB) > 25,000
> 25,000
> 25,000
> 25,000
K-562
MOLT-4
RPMI-8226
SR > 25,000
breast cancer
MCF7
HS 578T
MDA-MB-435
NCI/ADR-RES
T-47/D
> 25,000
> 25,000
<  2.5
> 19,000
13,600
melanoma
LOX IMVI
MALME-3M
SK-MEL-2
SK-MEL-5
SK-MEL-28
UACC-257
UACC-62
> 25,000
< 2.5
>25,000
< 2.5
>25,000
> 25,000
< 2.5
colon cancer
HCC-2998
HCT-116
HT29
SW-620
367
< 2.5
> 25,000
> 25,000
Cancer cell lines LC50 (nM)
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2.6 nM). Additionally, the enantiomer, (–)-irciniastatin A, did not display any inhibition 
of protein translation (~20% inhibition even at 10 µM) or cytotoxicity (GI50 >1000 nM) 
in HeLa cells.11,12 This data illustrates that (+)-irciniastatin A (1.1) is an enantio-specific 
inhibitor of protein synthesis.  
Usui also reported that the tumor growth inhibition activity of (+)-irciniastatin A 
(1.1) arises from activation of stress-activated protein kinases, such as JNK and p38, that 
in turn leads to apoptosis.11 The mechanism of induction of JNK and p38 by (+)-
irciniastatin A (1.1) was the same for onnamide A and theopederin B (1.4), members of 
the pederin family of natural products.13  
1.2.4 De Brabander’s Biological Studies 
De Brabander and coworkers evaluated the cytotoxicity of (+)-irciniastatin A 
(1.1) against a series of cancer cell lines (Table 1.3), again after completion of a total 
synthesis.10,14 To their surprise, synthetic (+)-irciniastatin A (1.1), constructed in their 
laboratories, did not reveal the highly differential cytotoxicity2 as previously reported by 
Crews and coworkers. All cell lines employed for this study resulted in potent 
cytotoxicity in the low nanomolar range. They also evaluated (+)-irciniastatin A (1.1) for 
protein translation inhibitory properties and discovered that (+)-irciniastatin A (1.1) was 
10 times more potent than mycalamide A (1.5) (28 nM vs 238 nM) in their in vitro 
assays. De Brabander, in collaboration with Roth, also disclosed a forward genetic screen 
of (+)-irciniastatin A (1.1) employing C. elegans that demonstrated 1.1 binds to the 
ribosome to induce cell death. In addition, they demonstrated that (+)-irciniastatin A (1.1) 
! 8!
does not possess the same potent vesicant activity as possessed by the pederins, when 
employing a mouse ear-swelling test (MEST).7 
Table 1.3. (+)-Irciniastatin A (1.1) Biological Evaluations by De Brabander and 
Coworkers 
!
!
!
!
!
!
!
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1.3 Selected Total Syntheses of (+)-Irciniastatin A (1.1) (Psymberin): Key 
Disconnections and End Game Strategies  
 Since the De Brabander seminal total synthesis,10 there have been six other total 
syntheses of (+)-irciniastatin A (1.1) (psymberin) to date,10,12,15-19 including one report 
from our Laboratory.16 However, at the start of our synthetic endeavor towards (–)-
irciniastatin B (1.2), there had been no reported total synthesis of 1.2. Indeed, the total 
synthesis of (–)-irciniastatin B (1.2) was only recently achieved in our laboratory.20,21 Our 
successful synthetic strategy to the construction of 1.2 will be outlined in Chapter Two. 
Cell line IC50 (nM) GI50(nM)
BJ
normal fibroblast
BJHtert
telomerase immortalized fibroblast
10.43 0.14
4.29 0.3
H2126
non-small cell lung tumor 0.45 0.13
HCT116
colon tumor 0.52 0.40
HT1080
fibroblast tumor 0.43 0.24
IGROV1
ovarian tumor 2.40 1.03
KM12
colon tumor 0.30 0.20
MDA-MB-231
breast tumor 0.61 0.23
PC3
prostate tumor 1.64 0.53
SKMEL2
melanoma tumor 0.71 0.22
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This subchapter will outline the various strategies employed in selected total syntheses of 
(+)-irciniastatin A (1.1) (psymberin). 
1.3.1 The De Brabander Synthesis of (+)-Irciniastatin A (1.1) (Psymberin) and 
Structural Confirmation 
 De Brabander and coworkers set out to construct psymberin to determine the 
structural relationship between (+)-irciniastatin A and (+)-psymberin.10,22 At the outset of 
this endeavor, the relative stereochemical configuration at C(4) was unknown and the 
configuration at C(8) had conflicting assignments.1,2 The De Brabander synthetic strategy 
therefore required access to all four possible C(4)-C(8) diastereomers (Scheme 1.1). 
Their retrosynthetic strategy first involved a disconnection at the amide leading to acid 
chloride 1.9 and methoxy-imidate 1.10. Both stereochemical configurations of the N,O-
aminal moiety were envisioned to be constructed via reduction of the resulting N-acyl-
methoxy-imidate. The epimeric acid chlorides 1.9 would be constructed from a common 
intermediate derived from D-mannitol. Methoxy imidate 1.10 in turn would be accessed 
via a substrate controlled aldol reaction between aryl aldehyde 1.11 and ethyl ketone 
1.12. 
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Scheme 1.1. Retrosynthetic Analysis by De Brabander and Coworkers 
 
 
 
!
  
 
Once ketone 1.12 was elaborated to nitrile 1.13, the nitrile had to be converted to 
the methoxy-imidate before the final coupling with the acid side chain (Scheme 1.2). 
Towards this end, nitrile 1.13 was treated with the Ghaffar-Parkins23 catalyst 1.14 to 
effect hydrolysis of the nitrile to the amide. Both 4-methoxybenzyl (PMB) ethers were 
removed under hydrogenolysis conditions and peracetylated. Amide 1.15 was then 
treated with Me3OBF4 and poly(4-vinylpyridine) to furnish methoxy-imidate 1.16, 
which was treated with acid chlorides 1.17 and 1.18 to provide the corresponding acyl-
methoxy-imidates. Upon reduction and saponification steps, a separable mixture of 1.1 
and 1.19 (71:29) from 1.17 and an inseparable mixture 1.20 and 1.21 (75:25) from 1.18 
were isolated. Since the spectral data of natural (+)-irciniastatin A (1.6) and (+)-
psymberin (1.8) were taken in different solvents, their exact stereochemical relationship 
was not resolved at the time of isolation. De Brabander conducted NMR studies on all 
four diastereomers in both solvents and determined that 1.1 is the correct structure for 
both irciniastatin A and psymberin. This seminal total synthesis not only established 
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unamibguously the absolute stereochemical configuration of psymberin but also proved 
that irciniastatin A and psymberin are identical.  
In summary, De Brabander accomplished the total synthesis of (+)-irciniastatin A 
(1.1) with a longest linear sequence of 21 steps from commercially available starting 
materials in an overall yield of 6.1%. 
Scheme 1.2. Total Synthesis of (+)-Irciniastatin A (1.1) (Psymberin) and its Structural 
Confirmation 
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1.3.2 The Schering-Plough Synthesis of (+)-Irciniastatin A (1.1)  
 In 2007, a group at the Schering-Plough Research Institute achieved the second 
total synthesis of (+)-irciniastatin A (1.1).15,24 They elected to disconnect the complex 
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structure at C(9)-O bond to provide enamide 1.22 (Scheme 1.3). The tetrahydropyran 
core was envisioned to be constructed via a novel (diacetoxyiodo)benzene-mediated 
oxidative cyclization,25 a method previously developed in their laboratories. Enamide 
1.22 would in turn be derived from the unions of amide 1.23, silyl enol ether 1.24, and 
aldehyde 1.25.   
Scheme 1.3. Retrosynthetic Analysis by the Schering-Plough group 
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 In the forward direction, aldehyde 1.25 was shown to undergo Mukaiyama aldol 
reaction in good yield (76% as pure isomer, dr = 5:1) with silylenol ether 1.24 (Scheme 
1.4). The ketone was then subjected to chelation-controlled reduction, mediated by 
catecholborane26 to furnish diol 1.26 with excellent diastereoselectivity (dr = 15:1). Diol 
1.26 was bisacetylated, followed by removal of the benzyl ether, Dess-Martin 
periodinane oxidation,27 and Takai olefination28 to furnish vinyl iodide 1.27. A Buchwald 
union29 between vinyl iodide 1.27 and amide 1.23 completed construction of the full 
carbon skeleton of the target natural product. Treatment under basic conditions next led 
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to hydrolysis of both acetate groups and one TIPS ether. The free phenol was selectively 
acetylated with acetic anhydride. Enamide 1.28 was exposed to PhI(OAc)2 to mediate 
cyclization, which proceeded in good yield (60% for two major diastereomers, 1:1). The 
secondary hydroxyl in turn was acetylated, followed by hydrogenolysis to furnish 1.29 
and 1.30. To reveal the terminal olefin, the diastereomers were separated and exposed to 
o-nitrophenylselenocyanate, followed by treatment with H2O2.30 The intermediates were 
then treated with TBAF at 50 °C to achieve global deprotection to (+)-irciniastatin A 
(1.1) (63% over three steps) and epi-C(8)-epi-C(9)-irciniastatin A (1.31). 
In summary, the group at Schering-Plough completed the total synthesis of (+)-
irciniastatin A (1.1) with a longest linear sequence of 25 steps from commercially 
available starting materials in an overall yield of 2.5%. The cornerstone of their strategy 
was the PhI(OAc)2 mediated oxidative cyclization to construct the trans-tetrahydropyran 
core. 
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Scheme 1.4. Total Synthesis of (+)-Irciniastatin A (1.1) by the Schering Plough Group 
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1.3.3 The Crimmins Synthesis of (+)-Irciniastatin A (1.1) 
 Crimmins and coworkers reported their successful total synthesis of (+)-
irciniastatin A (1.1) in 2009.17 Retrosynthetically, they disconnected 1.1 at the amide 
linkage to furnish acid chloride 1.32 and N,O-aminal 1.33 (Scheme 1.5). The N,O-aminal 
moiety was then envisioned to be constructed via a Curtius rearrangement16,31,32 of a 
carboxylic acid derived from benzyl ether 1.34. Construction of 1.34 in turn would be 
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achieved via stereoselective addition of silylenol ether 1.35 to the oxocarbenium ion 
derived from acetate 1.36.  
Scheme 1.5. Retrosynthetic Analysis by Crimmins and Coworkers 
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 The key union of acetate 1.36, constructed from 2-deoxy-D-ribose in 9 steps, and 
silylenol ether 1.35 was achieved via a BF3OEt2 mediated coupling to provide ketone 
1.34 with excellent diastereoselectivity (dr >20:1) (Scheme 1.6). The high level of 
stereoselectivity can be explained by pseudoaxial addition of 1.35 to the oxocarbenium 
ion. The oxocarbenium ion adopts conformation 1.37, which is favored due to through-
space stereoelectronic stabilization of the oxocarbenium ion by the axial TBS ether.33  
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Scheme 1.6. Elaboration to Ketone 1.34 
 
 
 
 
 With ketone 1.34 in hand, Crimmins continued the synthesis with elaboration to 
N,O-aminal 1.33 (Scheme 1.7). Stereoselective reduction of 1.34 was achieved via 
Corey-Bakshi-Shibata protocol34 employing the (R)-CBS reagent to provide alcohol 1.38 
as a single diastereomer. The secondary TBS ether was then hydrolyzed with 
concomitant lactonization to furnish 1.39. The alcohols were next reprotected as TBS 
ethers and the benzyl ether was removed under hydrogenolysis conditions. Alcohol 1.40 
was then oxidized to the corresponding acid, which underwent a Curtius 
rearrangement16,31,32 to install the N,O-aminal moiety, furnishing 1.33 in 76% yield with 
complete retention of stereochemical configuration. The union of 1.33 with acid chloride 
1.32 proved challenging; however, Crimmins discovered that employing i-PrMgCl as the 
base successfully provided amide 1.42 in an excellent 87% yield. The final global 
deprotection was then achieved with TAS-F35,36 in DMF to furnish (+)-irciniastatin A 
(1.1) in 94% yield.   
 
 
TIPSO
CO2Me
OTIPS
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O
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OMe
BnO OTBS BF3•OEt2
CH2Cl2, -40°C
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OH
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CO2Me
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O
OTBS
H
BnO
HMeO
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1.36
1.34
R=TBS
1.37
H
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Scheme 1.7. Completion of (+)-Irciniastatin A (1.1) by Crimmins and Coworkers 
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In summary, Crimmins and coworkers achieved the total synthesis of (+)-
irciniastatin A (1.1) with a longest linear sequence of 19 steps from commercially 
available materials, with a 6% overall yield. Highlights in the synthetic sequence include 
the stereoselective silylenol ether-oxocarbenium ion union, Curtius rearrangement to 
install the N,O-aminal, and a late-stage union of N,O-aminal 1.33 with acid chloride 1.32.  
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O
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1.3.4 The Floreancig Synthesis of (+)-Irciniastatin A (1.1)  
 Floreancig and coworkers18 set out to construct (+)-irciniastatin A (1.1) via a 
multicomponent sequence that includes nitrile hydrozirconation,37 acylation,38 and 
nucleophilic addition (Scheme 1.8). The Floreancig group had applied this strategy 
toward the construction of several amide scaffolds.39,40 This sequence was envisioned to 
begin with hydrozirconation of nitrile 1.45, followed by acylation with acid chloride 1.44. 
The resulting N-acyl-imine 1.43 would then be trapped by methanol to furnish the 
complete carbon skeleton of (+)-irciniastatin A (1.1).  
Scheme 1.8. Retrosynthetic Analysis by Floreancig and Coworkers 
!
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 The proposed multicomponent coupling proved to be a challenge (Table 1.4). 
Nitrile 1.48 was treated with Cp2ZrHCl, then acylated with acid chloride 1.47 followed 
by addition of MeOH to result in a mixture of diastereomeric N,O-aminals, with a 1:3 
ratio, where the undesired isomer predominated (Table 1.4, entry 1). Addition of 
Mg(ClO4)2 enhanced the selectivity of the desired isomer to 3:1, but only proceeded in a 
very low overall yield (Table 1.4, entry 2). Floreancig and coworkers reasoned that a 
bulkier and less reactive source of methanol would improve selectivity and yield. Indeed, 
addition of 2 eq of Mg(ClO4)2 and (MeO)3CH resulted in a 3:1 mixture, albeit again with 
low overall yield (~20%) (Table 1.4, entry 3). In order to improve further the efficiency 
!19!
of the transformation, Zn(OTf)2 was employed as the Lewis acid, which in this case 
resulted in lower stereoselectivity (~1.5:1), but higher yield (Table 1.4, entry 4). The 
crude mixture was subsequently treated with TBAF to result in hydrolysis of the silyl 
ethers, lactonization and loss of the benzoate to provide (+)-irciniastatin A (1.1) in 27% 
yield and epi-C(8)-irciniastatin A in 12% yield. Removal of the benzoate group was 
rationalized by the production of Bu4NOH during the removal of the silyl ethers.  
Table 1.4. Hydrozirconation/Acylation Sequence to the Construction of (+)-Irciniastatin 
A (1.1)  
 
 
 
!
 
 
Not withstanding the aforementioned difficulties, the Floreancig synthesis to (+)-
irciniastatin A (1.1) proves to be the shortest linear sequence to date (14 steps, 4.4% 
overall yield). Their successful multicomponent sequence approach to construct directly 
the N,O-aminal significantly contributes to the brevity of this synthetic route. 
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O OH
O
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H
H
OMe
N
H
O
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Entry Lewis Acid "MeOH" source Yield dr
1 None MeOH "Less Efficient" 1:3
2 Mg(ClO4)2 MeOH 3:1"Less Efficient"
3 Mg(ClO4)2 (MeO)3CH ~20% single step 3:1
4 Zn(OTf)2 (MeO)3CH 27% over 2 steps
12% epi-C(8)-Irciniastatin A
1.5:1
O
(+)-Irciniastatin A (1.1)
1.47
1.48
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1.4 Structure Activity Relationship Studies of Irciniastatin Analogues 
1.4.1 The De Brabander Analogue Study 
 The structural similarities between the irciniastatins and pederins would suggest 
that they possess similar biological functions. On the other hand, notable differences in 
structure and biological profile may indicate they have different biological mechanisms. 
De Brabander and coworkers set out to construct a hybrid between the two families of 
natural products, psympederin (1.49), in order to probe how differences in the molecular 
structure influence biological function.41 Psympederin (1.49) was designed to retain the 
irciniastatin’s acyclic side chain, but the dihydroisocoumarin was removed.  
Construction of psympederin (1.49) began with an 8-step sequence from diol 
1.52, an intermediate from their (+)-irciniastatin A (1.1) synthesis, to provide amide 1.53 
(Scheme 1.9). Installation of the side chain was achieved by methoxy-imidate formation 
from 1.53, acylation with acid chloride 1.17, and in situ reduction to the acyl-N,O-aminal. 
Final saponification removed the remaining protecting groups to furnish psympederin 
(1.49) and epi-C(8)-psympederin (1.50) as a separable mixture (1:4) of diastereomers.  
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Scheme 1.9. Synthesis of Psympederin (1.49) and epi-C(8)-Psympederin (1.50) 
 
 
 
 
 
 
De Brabander and coworkers evaluated the cytotoxic activity of the epimers of 
psympederin (1.49 and 1.50), (+)-irciniastatin A, and the C(8) and C(4)-epimers (1.19 
and 1.20, respectively)10 against a series of human tumor cell lines (Table 1.5).41 
Inverting the stereochemical configuration of the N,O-aminal (1.19) and at C(4) (1.20) 
resulted in a decrease in cytotoxicity across all cell lines tests, but inhibition of 
proliferation of the cancer cell lines remained (37-762 nM). Most interestingly, 
psympederin 1.49 displayed a dramatic decrease in cytotoxicity (~1000 fold) compared to 
(+)-irciniastatin A (1.1). epi-C(8)-Psympederin 1.50 displayed no cytotoxic activity 
against three of the four cell lines evaluated, in comparison with epi-C(8)-irciniastatin A 
(1.19), which displayed moderate to good activity. This result suggests that the 
dihydroisocoumarin fragment is critical to the cytotoxic activity of the irciniastatins, but 
is not important for the pederins. In addition, removal of the side chain in amide 1.51 
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resulted in complete loss of activity (Table 1.6), which suggests that the side chain is 
required for high levels of cytotoxicity. 
Table 1.5. Cytotoxicity of De Brabander’s Analogues Against Human Cancer Cell Lines 
!
!
!
!
 
 
 
 
 
 Since the members of the pederin family such as mycalamide A (1.5) are 
eukaryotic protein translation inhibitors,42 De Brabander hypothesized that (+)-
irciniastatin A (1.1) and the analogues may also possess this biological function, because 
of their similarities in chemical structure. De Brabander and coworkers evaluated their 
analogues for protein inhibition in both cell-based and in vitro assays (Table 1.6).14 In the 
cell-based assays, psympederin 1.49 and the epimers 1.20 and 1.19 displayed marked 
decrease in potency in inhibiting protein translation in both HeLa and SK-MEL-5 cells. 
Removal of the side chain (1.51) resulted in loss of all inhibition activity. In the in vitro 
assays of these analogues, De Brabander and coworkers were surprised to observe that 
Compound SK-MEL-5
0.45 ± 0.01 0.98 ± 0.12 2.29 ± 0.13Irciniastatin A (1.1)
KM12 PC3 T98G
1.37 ± 0.06
epi-C(8)-Irciniastatin A (1.19) 37.1 ± 5.5 200.2 ± 27.6 352.0 ± 12.1 85.8 ± 48.4
epi-C(4)-Irciniastatin A (1.20) 126.08 ± 8.6 346.5 ± 102.8 762.8 ± 70.0 186.7 ± 51.3
psympederin (1.49) 710.9 ± 35.8 821.8 ± 89.1 >1000 >1000
epi-C(8)-psympederin (1.50) >1000 255.5 ± 11.4 >1000 >1000
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psympederin 1.49, and epimers 1.20 and 1.19 were only 10 to 20-fold less active 
compared to (+)-irciniastatin A (1.1). The significant difference in the activities between 
the two assays suggests that removal of the dihydroisocoumarin and changes in 
stereochemical configuration affects other processes in the cell-based assay outside of the 
ribosome. Protein inhibition by psympederin 1.49 only decreased by 20-fold in the in 
vitro assays, suggesting that the dihydroisocoumarin is important for inducing 
cytotoxicity and not for protein translation inhibition.  
Table 1.6. Cytotoxicity and Protein Inhibition of De Brabander’s Analogues 
 
 
 
 
In order to understand the inconsistencies between the in vitro and cell-based 
assays for protein inhibition, De Brabander and coworkers14 measured the intracellular 
concentration of (+)-irciniastatin A (1.1) and the three synthetic analogues in question 
(Table 1.7). The HeLa cells were incubated for 2 h with 100 nM of each respective 
compound. The intracellular concentration of epimers 1.19 and 1.20 was about 20-fold 
less than that of (+)-irciniastatin A (1.1). Furthermore, psympederin’s intracellular 
concentration was below the limit of detection. Therefore, the difference in the two 
assays was presumably due to a difference in cellular uptake of the compounds. 
0.27
SK-MEL-5
cytotoxicity (IC50, nM)
Hela
0.64(+)-Irciniastatin A (1.1)
psympederin (1.49)
28
>1000 >1000 641
mycalamide A (1.5) 2.52 3.79 238
>1000 >1000 >10,000
2.2 11
59
>10,000
1650 578
64
>10,000
Translation Inhibition (EC50, nM)
in vitro assay HeLa
cell-based Assay
SK-MEL-5
1.51
618.6 352
346
318
epi-C(4)-Irciniastatin A (1.20)
epi-C(8)-Irciniastatin A (1.19) 2200
4950 496
843
>1000 762.8
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Table 1.7. Intracellular Concentration of (+)-Irciniastatin A (1.1) and Analogues in HeLa 
Cells 
 
 
!
1.4.2 The Schering-Plough Group Analogue Study 
 The group at Schering-Plough had constructed epi-C(8)-epi-C(9)-irciniastatin A 
1.31 via their synthetic route to irciniastatin A (1.1).15,43 They evaluated the cytotoxicity 
of 1.31 against a series of human cancer cell lines, and found that 1.31 displayed 
significant loss of cytotoxic activity compared to (+)-irciniastatin A (1.1), suggesting the 
importance of the stereochemical configuration at both C(8) and C(9) (Table 1.8).  
 
 
 
 
 
 
 
 
intracellular concentration (mM)
7.14
0.21
0.31
<LD
(+)-Irciniastatin A (1.1)
epi-C(4)-Irciniastatin A (1.20)
epi-C(8)-Irciniastatin A (1.19)
psympederin (1.49)
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Table 1.8. Antitumor Activity of 1.31 versus (+)-Irciniastatin A (1.1) by Schering-Plough 
(IC50 nM) 
!
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The Schering-Plough group conducted their next SAR study on the side chain 
(Table 1.9). Substantial reduction in cytotoxicity resulted when the side chain was 
replaced with a methyl group in compounds 1.54 and 1.55. Next, the function of the 
terminal olefin was examined. Compounds 1.56 and 1.57 replaced the terminal olefin 
with a primary hydroxyl group. Analogue 1.56 still retained good cytotoxicity (260 nM), 
however the epimer 1.57 lost all activity (>10,000 nM), which suggests the terminal 
olefin plays an important role in the biological mode of action responsible for potent 
cytotoxicity. Next, a phenyl group was employed to mimic the electronic properties of 
the terminal olefin. Analogues 1.58 and 1.59 were constructed without substitution at 
C(4) and C(5), which resulted in loss of activity (>10,000 nM). When the appropriate 
O
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Irciniastatin A (1.1)
9
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9
epi-C(8)-epi-C(9)-Irciniastatin A (1.31)
irciniastatin A
(1.1)
epi-C(8)-C(9)-irciniastatin A 
(1.31)
ACHN kidney0.76 ± 0.07 6800 ± 244
prostate0.30 ± 0.03 3800 ± 301
H226 lung0.18 ± 0.02 2400 ± 431
colon0.81 ± 0.14 4900 ± 187
lung0.42 ± 0.02 4600 ± 68
MB231 breast0.27 ± 0.01 4200 ± 174
cell lines human tissue tytpe
DU145
HCT116
HOP62
MB435 melanoma0.28 ± 0.03 3600 ± 155
MKN45 gastric0.28 ± 0.02 5200 ± 195
prostate0.19 ± 0.02 3100 ± 341 PC3
colon0.82 ± 0.04 4800 ± 177
normal0.84 ± 0.08 n.d. NHDF
SW620
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substitution was added to the phenyl analogues, 1.60 displayed good levels of 
cytotoxicity (32 nM), while 1.61 possessed moderate levels (615 nM). The biological 
data from these analogues suggests that the π-character in the side chain, as well as the 
substitution at C(4) and C(5), are important for the cytotoxic properties of (+)-
irciniastatin A (1.1).  
Table 1.9. Activity of Side Chain Analogues against HOP62 Lung Cancer Cell Line 
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 Although the only difference between (+)-irciniastatin A (1.1) and (–)-irciniastatin 
B (1.2) is the oxidation state at C(11), 1.2 displays a 10-fold increase in cytotoxic activity 
compared to 1.1.1 In order to probe the biological function of the C(11) oxygen, the 
Schering-Plough group set out to construct C(11)-deoxy-irciniastatin A (1.68). In 
addition, removal of the functionality in the tetrahydropyran core would simplify the 
synthesis. Full carbon skeleton 1.63 was constructed from ester 1.62 in 12 synthetic steps 
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1.57
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(Scheme 1.10). Oxidative cyclization promoted by PhI(OAc)2 was achieved in 89% yield, 
followed by acetylation of secondary hydroxyl group and debenzylation provided a 
mixture of four diastereomers. The diastereomers were separated via flash 
chromatography. Final elaboration to the C(11)-deoxy analogues required conversion of 
alcohols 1.64, 1.65, 1.66, and 1.67 to the o-nitrophenyl selenides, which upon oxidization 
in the presence of H2O2,30 and global deprotection with TBAF revealed C(11)-deoxy-
irciniastatin A (1.68) and corresponding epimers 1.69, 1.70, and 1.71.  
Scheme 1.10. Synthesis of C(11)-Deoxy-Irciniastatin A Analogues 
!
!
!
!
!
!
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The C(11)-deoxy-irciniastatin A analogues were then tested against a variety of 
human cancer cell lines (Table 1.10).43 The C(11)-deoxy-irciniastatin A congener (1.68) 
displayed very potent cytotoxicity and was 3-10 times more active compared to (+)-
irciniastatin A (1.1). Epimer 1.71 also displayed potent activity in the nanomolar range 
(1.6 – 8.7 nM). These results strongly suggest the hydrogen bond donating ability of the 
C(11) hydroxyl and a polar C(11) substituent are not important for cytotoxicity. 
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1.66 ,epi-C(8)
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1. o-NO2PhSeCN, PBu3, THF
2. H2O2, THF, 50 °C
3. TBAF, THF, rt to 50 °C
63% over three steps
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H
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O
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8
15
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9
E/Z = 5:1
1.62
1.63
1.68, C(11)-deoxy-Irciniastatin A
1.69, epi-C(8)-epi-C(9)-C(11)-deoxy-Irciniastatin A
1.70 ,epi-C(8)-C(11)-deoxy-Irciniastatin A
1.71, epi-C(9)-C(11)-deoxy-Irciniastatin A
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Table 1.10. Biological Evaluation of C(11)-Deoxy-Irciniastatin A Analogues (IC50 nM) 
 
 
 
 
 
1.4.3 The Iwabuchi Analogue Study 
 The Schering-Plough group illustrated that the terminal olefin in the side chain of 
(+)-irciniastatin A (1.1) can be replaced with an electronically similar moiety such as a 
phenyl group, and still retain potent cytotoxicity. Subsequently, Iwabuchi and coworkers 
constructed “alkymberin” (1.80), where the terminal olefin is substituted with an alkyne 
moiety.12 They envisioned that the alkyne could be employed as a chemical handle for 
coupling reporter tags via click chemistry.44 The construction of alkymberin (1.80) begins 
with TES protection of propargyl bromide 1.72 (Scheme 1.11) to furnish bromide 1.73, 
which was treated with the alkoxide of propargyl alcohol to provide di-yne 1.74. Directed 
reduction followed by Sharpless epoxidation45 furnished epoxide 1.75 in 79% yield with 
good enantioselectivity (94% ee). Chemoselective epoxide opening was then achieved 
with Eu(OTf)3 to furnish the desired 1,2-diol 1.76 (4:1 mixture with the 1,3-diol). 
Construction of primary alcohol 1.77 was next achieved by a three-step sequence: 
protection of primary hydroxyl group as a pivalate ester; SEM protection of the 
secondary hydroxyl group; and reductive removal of the pivalate ester. Alcohol 1.77 was 
n.d.
1.691.68
0.265 ± 0.008 n.d.
0.149 ± 0.005 n.d. n.d.
0.034 ± 0.004 n.d. n.d.
0.055 ± 0.002 177 ± 6 46 ± 7
8.7 ± 0.18 ACHN
1.6 ± 0.27
3.0 ± 0.12
5.9 ± 0.18
1.70 1.71 cell line
0.142 ± 0.007 n.d. n.d.
0.076 ± 0.004 n.d. n.d. 3.9 ± 0.48
5.3  0.15 MB231
MKN45
human tissue
Kidney
DU145 prostate
H226 lung
HOP62 lung
breast
gastric
0.073 ± 0.006 n.d. n.d. 2.9 ± 0.21 prostate
0.160 ± 0.015 n.d. n.d. 6.1 ± 0.22 colon
PC3
SW620
.066 ± 0.004 n.d. n.d. 3.8 ± 0.1 normalNHDF
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then directly oxidized to the carboxylic acid employing 1-Me-AZADO.46 The carboxylic 
acid in turn was converted to the mixed anhydride and coupled to the N,O-aminal 1.79 
followed by global deprotection to provide alkymberin 1.80.  
Scheme 1.11. Synthesis of Alkymberin (1.80) 
!
!
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 Iwabuchi and coworkers also constructed the enantiomer of (+)-irciniastatin A 
(1.1), (–)-irciniastatin A (1.88).12 They were interested in whether the secondary 
metabolite behaved as a “ligand” or “chemical reagent” in cells, since the C(8) N,O-
aminal could act as a good electrophilic reagent. To this end, they constructed the 
necessary fragments with the opposite stereochemical configurations and achieved the 
unions required to construct (–)-irciniastatin A (1.88) (Scheme 1.12). 
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Scheme 1.12. Synthesis of (–)-Irciniastatin A (1.88) 
 
 
 
 
 
 
 The two synthetic analogues were evaluated for cytotoxicity against HeLa cells. 
Alkymberin (1.80) possessed high levels of activity (GI50 = 1.2 nM compared to 0.2 nM 
for 1.1). Therefore, alkymberin (1.80) can be employed as a probe to study the 
irciniastatin’s biological mode of action. The enantiomer (–)-irciniastatin A (1.88) 
however, displayed no cytotoxic activity (GI50 > 1000 nM). Although (–)-irciniastatin A 
(1.88) possesses a highly electrophilic N,O-aminal moiety, the enantiomer was unable to 
induce any cytotoxicity in HeLa cells, suggesting that (+)-irciniastatin A acted as a 
enantio-specific ligand to the target protein, rather than simply an electrophilic reagent.   
1.4.4 The Floreancig Analogue Study 
 Floreancig and coworkers also constructed several synthetic analogues to probe 
the biological mode of action of (+)-irciniastatin A (1.1). Floreancig, similar to De 
Brabander, was also interested in how the differences in structure of the irciniastatins and 
O
O
OH
1. LiAlH4, THF, 0 °C to reflux
2. 3-pentanone, TsOH•H2O
    4 Å sieves
1. BzCl, Et3N, DMAP, CH2Cl2
2. 10% HCl, MeOH, 53% over 4 steps
3. TsCl, Et3N, DMAP, CH2Cl2, 0 °C then DBU
    78%
BzO
O
1.
OPMB
n-BuLi, BF3•OEt2, THF –78 °C, 70%
2. K2CO3, MeOH, 79%
3. TEMPO, PhI(OAc)2, CH2Cl2, 76%
OHC
OPMB
OH
O
OMe
OBn
O
H
OTBS
H
O
1.81 1.82
1.83
1.84
1.85
1.86
16 steps
HO
O
O
Et Et
O
OSEM
OMe
OPiv
1.87
9 steps
O
OMe
N
H
OH
O
OH
OMe
O OH
OOH
HO
H
H
(–)-Irciniastatin A (1.88)
!31!
the pederins influence their biological activity (Table 1.11). Floreancig had synthesized 
hybrid analogue pedastatin 1.89, where the acyclic side chain was replaced with the 
pederate cyclic side chain.18 To their surprise, pedastatin 1.89 was 10-fold more potent 
than (+)-irciniastatin A (1.1). This new result suggests that pederin (1.3) and (+)-
irciniastatin A (1.1) may share the same binding site on the ribosome, and that the cyclic 
side chain of pederin and dihydroisocoumarin of (+)-irciniastatin A (1.1) play an 
important role vis-a-vis the high levels of cytotoxicity of (+)-irciniastatin A (1.1). In order 
to evaluate the biological function of the N,O-aminal, C(8)-desmethoxy psymberin (1.90) 
and C(10)-desmethoxy pedastatin (1.91) were constructed and evaluated for cytotoxic 
activity. Both analogues possessed potent activity, displaying only 10-fold less activity 
than the parent natural product/analogue, which importantly suggests that the N,O-aminal 
is not an electrophilic reagent for the protein target that is responsible for cytotoxicity, the 
same conclusion that Iwabuchi made from their analogue study. Taken together with the 
substantial loss in activity for the epi-C(8)-irciniastatin A analogues synthesized by De 
Brabander and the Schering-Plough group, the stereochemical configuration at C(8) is 
critical to the irciniastatin’s ability to adopt the favorable binding conformation. The 
natural C(8)-(S) configuration stabilizes the binding conformation and the unnatural C(8)-
(R) configuration destabilizes this conformation. Removal of the stereogenic center 
altogether does not stabilize nor destabilize the binding conformation, and thus retains 
potent activity. 
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Table 1.11. Biological Evaluation of Floreancig’s Analogues 
 
 
 
 
1.4.5 Summary of SAR Studies 
 Since their isolation, numerous biological and SAR studies have shed light on the 
biological mechanism of (+)-irciniastatin A (1.1) (psymberin) and (–)-irciniastatin B 
(1.2). A summary of these studies is presented in Figure 1.5. The difference in biological 
profiles associated with the structural differences of the alcohol (1.1) and the ketone 
(1.2), however, still remain unknown. In conjunction with designing and executing a 
synthetic route to construct (–)-irciniastatin B (1.2), we also aimed to construct synthetic 
analogues to determine the role that the C(11) substituent plays in the irciniastatins 
biological mechanism in an SAR study (Figure 1.6).  
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Figure 1.5. Summary of Analogues Studies for (+)-Irciniastatin A (1.1) 
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Figure 1.6. Proposed C(11)-Irciniastatin Analogues
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CHAPTER 2 Total Synthesis of (–)-Irciniastatin B 
Adapted with permission from An, C.; Hoye, T. A.; Smith, A. B. III. “Total Synthesis of 
(−)-Irciniastatin B and Structural Confirmation via Chemical Conversion to (+)-
Irciniastatin A (Psymberin)” Organic Letters 2012, 14, 4350-4353. Copyright 2012 
American Chemical Society. 
Adapted with permission from An, C.; Jurica, J. A.; Walsh, S. P.; Hoye, T. A.; Smith, A. 
B. III. “Total Synthesis of (+)-Irciniastatin A (a.k.a Psymberin) and (–)-Irciniastatin B” 
Journal of Organic Chemistry. 2013, 78, 4278-4296. Copyright 2013 American Chemical 
Society. 
2.1 Synthetic Strategy Toward (–)-Irciniastatin B 
Figure 2.1. (–)-Irciniastatin B 
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2.1.1 Retrosynthetic Analysis of (–)-Irciniastatin B (2.2) 
Our strategy to construct (–)-irciniastatin B (2.2)1,2 follows the same 
retrosynthetic disconnections as the earlier Smith synthesis of (+)-irciniastatin A (2.1).2,3 
The first disconnection begins at the amide linkage, leading to acid side chain 2.3 and 
Teoc-protected N,O-aminal 2.4 (Scheme 2.1). The acid-sensitive N,O-aminal moiety 
would be installed late in the synthesis, with complete retention of stereochemical 
configuration via a Curtius rearrangement,4 a strategy first developed and successfully 
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exploited by the Smith group’s 2002 synthesis of (+)-zampanolide, bearing a similar 
N,O-aminal group.5 Disconnection at C(16)-C(17) next provided aldehyde 2.5 and 2,6-
trans-tetrahydropyran 2.6, which we envisioned would be united via a substrate-
controlled aldol reaction. Aryl aldehyde 2.5 in turn would then derive by a [4+2] 
cycloaddition between known bis-silyl enol ether 2.76 and allene 2.8,7 while 2,6-trans-
tetrahydropyran 2.6 would arise via a 6-exo-tet-cyclization from epoxide 2.9. Epoxide 2.9 
in turn would be constructed via union of aldehyde 2.10 and ketene acetal 2.11, 
exploiting a vinylogous Mukaiyama aldol reaction to set the first stereogenic center.8 
Importantly, the requisite stereogenicity in tetrahydropyran 2.6 would be installed via 
three reagent-controlled asymmetric reactions.  
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Scheme 2.1. Retrosynthetic Analysis of (+)-Irciniastatin A (2.1) and (–)-Irciniastatin B 
(2.2) 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.2 Divergent Strategy to the Construction of (–)-Irciniastatin B (2.2) 
To achieve the requisite ketone oxidation state at C(11), the C(15) secondary 
hydroxyl in (+)-2.12, a late-stage intermediate employed in our synthesis of (+)-
irciniastatin A (1),3 was envisioned to be protected as a SEM ether, instead of a TBS ether 
employed earlier (Scheme 2.2). This protecting group was selected to permit the critical, 
selective deprotection of the neopentyl secondary TBS ether at C(11). The secondary 
alcohol would then be oxidized to the requisite ketone, followed by global deprotection to 
provide access to (–)-irciniastatin B (2.2). The advantage of this approach compared to 
our original strategy for (+)-irciniastatin A (2.1) would be ready access to a late-stage 
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intermediate [i.e., (+)-2.12] en route to both (+)-irciniastatin A (2.1) and (–)-irciniastatin 
B (2.2). Additionally, chemical modification of both the C(11) alcohol and ketone in late 
stage intermediates would permit access to analogues varying at the C(11) stereogenic 
center, thus permitting further exploration of the irciniastatin chemotype as a potent 
therapeutic lead. 
Scheme 2.2. Divergent Strategy to (+)-Irciniastatin A (2.1) and (–)-Irciniastatin B (2.2) 
 
 
 
 
 
 
 
 
2.2 Challenges Towards the Construction of (–)-Irciniastatin B (2.2) 
 Although the total synthesis of (+)-irciniastatin A (2.1) has been reported seven 
times since the original isolation,3,9-14 prior to beginning our synthetic endeavor, there had 
been no reported total synthesis of (–)-irciniastatin B (2.2). This is surprising since 2.2 
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was known to be 10-fold more active compared to 2.1.15 The reason for no successful 
total synthesis of (–)-irciniastatin B (2.2) might be attributed to the required manipulation 
of a late-stage intermediate such as 2.15 that possesses two highly sensitive moieties: a 
base sensitive ketone and an acid labile N,O-aminal. For example, we envisioned the 
tetrahydropyranone contributes to the base sensitivity in 2.15. Treatment with a base 
could lead to a retro-Michael-Michael sequence, converting the trans-tetrahydropyranone 
2.15 into the more thermodynamically favored cis-tetrahydropyranone 2.16 (Scheme 
2.3).16 Mechanistically, the first step would be deprotonation of the α-position, which 
would initiate a retro-Michael addition, opening the THP core. The thermodynamically 
favored product would then be formed upon cyclization via an oxa-Michael addition. 
Scheme 2.3. Base-Mediated Epimerization of trans-Tetrahydropyranone 
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 Treatment of 2.15 with acid would also result in undesired degradation products 
due to the sensitivity of the N,O-aminal moiety (Scheme 2.4).17 For example, upon 
exposure to a Brønsted or Lewis acid, ionization of methanol could result in acyliminium 
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ion 2.17. Acyliminium ion 2.17 could then be trapped by a nucleophile such as water to 
furnish the hydroxy-aminal 2.18. With these two synthetic challenges in mind, we were 
prudent in our selection of a suitable protecting group strategy that would lead to the 
successful construction of (–)-irciniastatin B (2.2). To this end, we selected SEM as the 
optimal alcohol protecting group because of its robust nature and its successful removal 
with the mildly basic fluoride reagent, TAS-F,18,19 as employed in our earlier synthesis of 
(+)-irciniastatin A (2.1).3  
Scheme 2.4. Acid Hydrolysis of N,O-Aminal 
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2.3 Synthesis of Acid Side Chain (–)-2.3 
Synthesis of the requisite acid side chain began via an asymmetric Brown 
allylation between 2-methyl-propene and commercially available (+)-isopropylidene 
glyceraldehyde (+)-2.19 (Scheme 2.5).9 Alcohol 2.20 was then treated with methyl iodide 
and sodium hydride to furnish methyl ether (+)-2.21 in 41% yield over the two steps with 
excellent stereochemical control (dr > 20:1). Removal of the acetonide was next achieved 
by treatment of (+)-2.21 with aqueous hydrochloric acid. The primary alcohol was in turn 
protected chemoselectively as pivalate ester (+)-2.22, followed by protection of the 
secondary alcohol as SEM ether (–)-2.23. Reduction with DIBAL-H provided primary 
alcohol (+)-2.24, which was then oxidized via a two-step Parikh-Doering20/Pinnick21 
oxidation sequence to provide the desired acid side chain (–)-2.3.  
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Scheme 2.5. Synthesis of Acid Side Chain (–)-2.3 
 
 
 
 
 
2.4 Synthesis of Aryl Aldehyde 2.5 
The requisite aryl aldehyde 2.5 was constructed via a Diels-Alder cycloaddition 
between 1,3-bis(trimethylsiloxy)-1,3-diene 2.7 (constructed in 3 steps),6 and dimethyl-
1,3-allene-dicarboxylate 2.8 (constructed in 2 steps)7 (Scheme 2.6). Their union was 
followed by a fluoride-mediated aromatization to furnish known homophthalate 2.2522 in 
good yield (42%–77%). Bis-phenol 2.25 was next protected as bis-SEM ether 2.26 
followed by chemoselective reduction to furnish aryl aldehyde 2.5. 
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Scheme 2.6. Synthesis of Aryl Aldehyde 2.5 
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2.5 Synthesis of trans-Tetrahydropyran (+)-2.6 
Figure 2.2. trans-Tetrahydropyran (+)-2.6 
!
!
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2.5.1 Synthesis of Bis-TBS Ether (+)-2.31 
We began the synthesis of trans-tetrahydropyran (+)-2.6 via monoprotection of 
commercially available 2,2-dimethyl-1,3-propanediol 2.27 (Scheme 2.7), followed by 
oxidation of the second hydroxyl group via the Parikh-Doering20 protocol to provide 
aldehyde 2.10. Treatment of aldehyde 2.10 and ketene acetal 2.118 employing the chiral 
oxazaborolidinone derived from L-tryptophan, led to a vinylogous Mukaiyama aldol 
reaction,8 thereby installing the first stereocenter to furnish (+)-2.29 as a single 
enantiomer. Mosher’s ester analysis demonstrated that the desired (R)-isomer was 
obtained.23,24 Alcohol (+)-2.29 was then protected as the TBS ether, followed by 
reduction of the methyl ester with DIBAL-H to furnish the corresponding allylic alcohol. 
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A second reagent controlled transformation, asymmetric epoxidation via the Sharpless25 
protocol, next provided the desired β-epoxide (+)-2.30 with 10:1 diastereoselectivity, 
which in turn was converted directly to the corresponding acid via a one-pot TEMPO26 
oxidation; subsequent methylation provided methyl ester (+)-2.31. 
Scheme 2.7. Synthesis of Bis-TBS Ether (+)-2.31 
 
 
 
 
 
 
2.5.2 Chemoselective Deprotection of Bis-TBS Ether (+)-2.31 
Chemoselective deprotection of the primary TBS ether was achieved by treatment 
of (+)-2.31 with hydrogen fluoride, buffered with pyridine (Scheme 2.8). Unfortunately, 
the acidic medium activates the epoxide to nucleophilic attack, leading to the formation 
of undesired pyran 2.33. Separation of the desired primary alcohol (+)-2.32 and pyran 
2.33 could be achieved by column chromatography. However, when the reaction was 
conducted on large scale (> 5 g), the purification via silica gel flash column 
chromatography became a challenge due the acid sensitivity of (+)-2.32. In order to 
isolate the desired product without the undesired conversion of (+)-2.32 to 2.33 during 
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the purification step, the crude mixture, after the deprotection step, was carried without 
further purification through the Parikh-Doering20 oxidation. At this stage, aldehyde (+)-
2.34 could be isolated from undesired pyran products via column chromatography 
without visible degradation. 
Scheme 2.8. Chemoselective Deprotection of Primary TBS Ether (+)-2.31 
 
 
 
 
2.5.3 One-Pot Paterson Aldol/Reduction Sequence: Completion of trans-
Tetrahydropyran (+)-2.6 
The final stereocenter required for the tetrahydropyran core was introduced via 
Paterson aldol union27,28 with aldehyde (+)-2.34 and 2-butanone, employing (−)-B-
chlorodiisopinocampheylborane (DIP-Cl) as the chiral Lewis acid. The desired β-
hydroxyketone 2.9 was obtained in 38% yield as a 6:1 (β:α) diastereomeric mixture 
(Scheme 2.9). The stereochemical outcome for the methyl ketone aldol reaction can be 
understood by a favorable boat transition state. This conformation minimizes the 
unfavorable steric interactions between one of the isopinocampheyl (Ipc) ligands and the 
ethyl substituent. On the other hand, the opposite stereochemical outcome would arise 
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minimize the steric interactions between the Ipc ligand and the methyl substituent of the 
boron enolate.  
Scheme 2.9. Stereochemical Rationale of Paterson Aldol Reactions 
 
 
 
 
 
 
The lower than expected yield realized on larger scale (38%, 500 mg) was 
explained by the formation of dioxaborinane 2.35 (Table 2.1). This unexpected side 
product was formed after completion of the aldol union. During the oxidative quench 
step, the boronate ester aldol adduct was not completely oxidized to aldol product 2.9, 
instead reduction of the aldol adduct leads to dioxaborinane 2.35. We had hypothesized 
that the source of hydride came from one of the Ipc ligands. In order to optimize the yield 
of 2.9, conditions for the oxidative quench step were screened (Table 2.1). We discovered 
that temperatures greater than –40 °C triggered the formation of 2.35 (Table 2.1, entries 1 
and 2). Therefore, upon completion of the aldol union, cryogenic temperatures (–78 °C to 
–65 °C) with m-CPBA employed as the oxidant instead of hydrogen peroxide resulted in 
the sole formation of the desired aldol product 2.9 (Table 2.1, entry 3), inhibiting the 
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undesired reduction pathway. Unfortunately, the product of the aldol union was obtained 
with no diastereoselectivity (1:1). The unexpected absence of facial bias was rationalized 
by our hypothesis that the aldol union was actually not stereoselective. However, in order 
to obtain a 6:1 dr (Table 2.1, entry 1), reduction of the boronate ester aldol adduct to 
dioxaborinane 2.35 must be stereospecific. Similar to a kinetic resolution, only the 
undesired α-isomer of the boronate aldol adduct was reduced to dioxaborninane 2.35, 
while the desired β-isomer was hydrolyzed to aldol product 2.9, resulting in the enhanced 
diastereoselectivity of 6:1.  
Table 2.1. Optimization of Oxidative Quench Conditions 
 
 
 
 
 
Evidence for the proposed mechanism of the above reduction began with 
formation of boronate aldol adduct 2.36 (Scheme 2.10). Under standard oxidative 
conditions, the expected aldol product 2.9 would be formed. However, in this case, when 
the reaction was warmed to temperatures greater than –40 °C, the reduction pathway 
proceeded. The hydride was delivered from one of the Ipc ligands via a 6-membered ring 
transition state, releasing one equivalent of α-pinene and 2.35. This mechanistic pathway 
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was recently confirmed by Menche and coworkers in their synthesis of 1,3-diols via Ipc-
mediated aldol/reduction sequence.29 All attempts to remove the boronate ester under 
oxidative conditions failed to provide the desired diol. Only acid treatment provided 
tetrahydropyran (–)-2.37 as a single diastereomer. Isolation of a single diastereomer at 
this stage confirms that the reduction pathway proceeds with stereospecificity and 
excellent diastereoselectivity. 
Scheme 2.10. Mechanistic Rationale for Reduction Product 2.35 
 
 
 
 
 
 
 
In order to obtain a higher diastereomeric ratio in the formation of 2.9 (6:1), the 
reduction pathway was induced after completion of the aldol reaction. With 2.9 in hand, 
we examined the acid-promoted cyclization to generate the tetrahydropyran core. 
Baldwin rules30 suggested that both the desired 6-exo-tet and undesired 7-endo-tet 
cyclization pathways could operate. However, the six-membered ring transition state, in 
conjunction with the electron-withdrawing nature of the ester, destabilizing the partial 
O OTBS
OMe
O O
H
O
+ (–)-DIPCl, Et3N
 Et2O, –78 °C to –40 °C
O O
∗
OTBS O
OMe
OB
O O
∗ ∗
OTBSB
BO O
∗
H OTBS O
OMe
O
O
OMe
O–40 °C to 0 °C
Camphorsulfonic Acid (CSA)
CH2Cl2
*
O*
HO
CO2Me
OH
OTBS
HH
Single Isomer
2.34
2.36
2.35
(–)-2.37
!51!
cationic character at the α-carbon under Lewis- or Brønsted-acidic conditions, suggested 
that the tetrahydropyran would predominate. Indeed, treatment with 20 mol % of 
camphorsulfonic acid (CSA) in methylene chloride achieved the desired 6-exo-tet 
cyclization, furnishing (+)-2.38 and (–)-2.39 with no trace of seven-membered ring 
congeners (Scheme 2.11). Fortunately, the trans- and cis-diastereomers could be readily 
separated by column chromatography to yield 2,6-trans-tetrahydropyran (+)-2.38 in 33% 
yield for the 2 steps. Methylation of the secondary hydroxyl group was then achieved 
(84% yield) by treatment with Me3OBF4 and proton sponge [1,8-
bis(dimethylamino)naphthalene] to complete the second-generation synthesis of the 2,6-
trans-tetrahydropyran core (+)-2.6. 
Scheme 2.11. Completion of trans-Tetrahydropyran (+)-2.6 
 
 
 
 
 
 
2.6 Fragment Unions 
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employed in our earlier (+)-irciniastatin A (2.1) synthesis. Unfortunately, we had 
discovered that the phenolic SEM ethers utilized as our protecting group strategy proved 
to be too labile in the synthesis of SEM ether 2.4. This subchapter will outline the 
problematic steps in this synthetic sequence while subchapters 2.7 and 2.8 will detail the 
application of a revised protecting group strategy employing 3,4-dimethoxybenzyl ethers 
toward the completion of (–)-irciniastatin B (2.2). 
2.6.1 Aldol Union and Elaboration Towards Acid (+)-2.43 
The union of tetrahydropyran (+)-2.6 with aryl aldehyde 2.5 (Scheme 2.12) was 
achieved via a substrate-controlled aldol reaction. Generation of the Z-boron enolate of 
(+)-2.6, achieved by treatment of (+)-2.6 with dichlorophenylborane,31 was followed by 
addition of aldehyde 2.5 to furnish (+)-2.40, the desired syn-aldol product, in 68% yield. 
The stereochemical outcome was dictated by 1,4-substrate stereoinduction.32 Subsequent 
chelation-controlled reduction,33 resulted in a mixture of the desired syn diol 2.41 and the 
corresponding lactone 2.42 (ca. 4:1) in 75% overall yield. The mixture was treated with 
LiOH, followed by addition of acetic acid (5% aqueous solution), to mediate 
lactonization, providing dihydroisocoumarin (+)-2.43 in 72% yield for the two steps. It is 
important to note, however, that the acetic acid required for lactonization often results in 
the unforeseen hydrolysis of one of the phenolic SEM ethers. Therefore, the pH of the 
reaction during the quench stage must be carefully monitored in order to obtain optimal 
yields. 
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Scheme 2.12. Fragment Union and Elaboration to Acid (+)-2.43 
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2.6.2 Curtius Rearrangement and Protecting Group Challenges 
At this juncture we called upon a Curtius rearrangement, the strategy that was 
previously exploited in our synthesis of (+)-zampanolide5 and (+)-irciniastatin A (2.1)3 to 
install the N,O-aminal (Scheme 2.13). In this case, acid (+)-2.43 was converted to the 
corresponding acyl azide, followed by thermal rearrangement in toluene (ca. 80 °C) to 
provide the isocyanate, which was intercepted by the addition of 2-trimethylsilylethanol 
to furnish the desired N,O-aminal (+)-2.12 (61%), with complete retention of 
configuration at the methyl ether carbon (determined by 1H NMR).  
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Scheme 2.13. Curtius Rearrangement and Protecting Group Challenges 
 
 
 
 
 
 
 
As outlined in subchapter 2.1.2, we envisioned the remaining secondary alcohol 
in N,O-aminal (+)-2.12 to be protected as a SEM ether, instead of TBS ether employed in 
our earlier (+)-irciniastatin A (2.1) synthesis.3 In order to construct (–)-irciniastatin B 
(2.2), installation of a SEM ether at C(15) was envisioned to permit orthogonal 
deprotection of the sterically hindered secondary C(11) TBS ether at a later step in the 
synthesis, which would permit installation of the requisite ketone. To our surprise, 
protection of (+)-2.12 not only proved to be extremely sluggish (50% yield), but also 
resulted in the heightened sensitivity of the phenolic SEM ethers (Scheme 2.13). Standard 
workup conditions and silica gel column chromatography (buffered with Et3N) resulted 
in a mixture of the desired SEM ether 2.4 and monophenol 2.44. For unexplained 
reasons, the introduction of a third SEM ether resulted in the increased sensitivity of the 
phenolic SEM ethers to acid-hydrolysis. Attempts at reprotection of the phenolic 
hydroxyls proved ineffective, even at elevated temperatures. Since the phenolic SEM 
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ethers were easily hydrolyzed at multiple points in the late-stage synthesis, a more robust 
protecting group strategy was required. 
2.7 Revising the Protecting Group Strategy 
2.7.1 Model Study-4-Methoxybenzyl Ether 
 4-Methoxybenzyl ether (PMB) was initially selected as a potential replacement 
for the phenolic SEM ethers because of the superior stability under acidic conditions and 
ease of removal under oxidative conditions (DDQ). A model study was therefore 
designed in order both to examine the feasibility of removing the PMB ethers in late-
stage intermediates and to assess the stability of the highly sensitive N,O-aminal moiety 
(Scheme 2.14). To this end, a Hirschmann mixture experiment was carried out.34 Mono-
PMB ether 2.45 was synthesized and mixed with a late-stage intermediate 2.46, which 
had a SEM ether hydrolyzed from earlier manipulations. The mixture was treated with 
DDQ. To our surprise, exposure to DDQ for three days at elevated temperatures (40 °C) 
resulted in no loss of the protecting group. Pleasingly, however, N,O-aminal 2.46 proved 
to be stable under standard PMB removal conditions.  
Scheme 2.14. Model Study-4-Methoxybenzyl Ether 
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2.7.2 Model Studies-3,4-Dimethoxybenzyl Ether (DMB) 
 From our model study, we learned the N,O-aminal moiety was stable when treated 
with DDQ for prolonged reaction times. Therefore, 3,4-dimethoxybenzyl ether (DMB) 
was next examined because this group was known to be much more sensitive to DDQ 
compared to PMB (Scheme 2.15). Bis-DMB ether 2.47 was constructed by protection of 
bis-phenol 2.25 with DMB-Br and K2CO3 in acetone. Bis-DMB ether 2.47 was then 
treated with the same standard deprotection conditions employed in the previous model 
study to achieve cleanly the hydrolysis of both protecting groups, providing bis-phenol 
2.25. Bis-DMB ether 2.47 also proved to be stable under the mild acidic conditions 
employed in the synthetic sequence.  
Scheme 2.15. Model Study-3,4-Dimethoxybenzyl Ether 
 
 
2.8 Fragment Union Employing the Revised Protecting Group Strategy 
 The synthesis toward (–)-irciniastatin B (2.2) continued with the newly designed 
DMB ether protecting group strategy. Reduction of the ester 2.47 with DIBAL-H 
furnished the aryl aldehyde 2.48 (Scheme 2.16). From here, the synthetic route continued 
in similar fashion to the sequence leading to (+)-irciniastatin A (2.1) as presented in 
subchapter 2.6. Aldol union31 between aldehyde 2.48 and ketone (+)-2.6 pleasingly 
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furnished a mixture of the desired syn diol 2.50 and lactone 2.51 (ca. 8:1), which upon 
treatment with LiOH followed by an acid work-up (50% AcOH) led to the desired acid 
(+)-2.52 in 69% yield for the two steps. This time, the DMB ethers proved to be stable 
under the acetic acid quench after saponification; no hydrolysis of the protecting groups 
was observed! With acid (+)-2.52 in hand, the corresponding acyl azide was generated 
and subjected to Curtius rearrangement conditions;5 the resulting isocyanate intermediate 
was treated with 2-trimethylsilylethanol to furnish the Teoc-protected N,O-aminal in 67% 
yield, again with complete retention of stereogenicity at C(8) (determined by NMR). The 
remaining secondary alcohol was then protected as the SEM ether (+)-2.53 in 82% yield. 
Importantly, the workup and purification steps proceeded without the formation of 
undesired side products. 
Scheme 2.16. New Protecting Group Strategy: Elaboration to N,O-Aminal (+)-2.53 
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 Employing the revised protecting group strategy successfully provided SEM ether 
(+)-2.53 in 26.5% yield over 5 steps (>300 mg synthesized), which represents a 3-fold 
improvement over our original protecting group strategy, to provide (+)-2.4 in 8.8% 
yield. The problem of facile hydrolysis of the protecting groups was thus overcome by 
utilizing robust 3,4-dimethoxybenzyl ethers. !
2.9 Amide Coupling to the Complete Carbon Skeleton of (–)-Irciniastatin B 
Achieving the requisite amide union to provide (+)-2.56 proved challenging 
(Table 2.2). The conditions employed in our earlier (+)-irciniastatin A (2.1) synthesis,3 
(Table 2.2, entry 1) involving LiHMDS as the base with mixed anhydride 2.54, resulted 
in low yields (ca. 15%). Warming the coupling reaction to 0 °C failed to enhance the 
efficiency of the transformation (Table 2.2, entry 2). Switching to a stronger base (n-
BuLi, Table 2.2, entry 3) resulted in a complex mixture of products with no desired 
product observed. We had predicted that the more electrophilic acid chloride 2.55, would 
be sufficiently reactive to undergo amide formation with the sterically hindered 
carbamate (+)-2.53. Unfortunately, employing LiHMDS as the base and acid chloride 
2.55 failed to react (Table 2.2, entry 4). Fortunately, conditions employed by Crimmins 
and coworkers,11 in their synthesis of (+)-irciniastatin A (1.1), namely the use of i-
PrMgCl as the base and acid chloride 2.55, provided the desired amide (+)-2.56 in 72% 
yield (Table 2.2, entry 5). Interestingly, the previous (+)-irciniastatin A (1.1) syntheses 
also required significant screening and optimization of this very challenging coupling, 
even though the substrates possessed almost identical structures, except for the different 
protecting groups.3,11,13 Therefore, slight differences in molecular structure, even in 
!59!
regions distal to the reactive site, seem to play a significant role in the successful 
construction of this challenging amide bond. 
Table 2.2. Amide Coupling Conditions 
!
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2.10 Final Elaboration to (–)-Irciniastatin B (2.2) 
2.10.1 Selective Deprotection and Oxidation  
Having arrived at the full carbon skeleton of (–)-irciniastatin B (2.2), we set out to 
effect the selective deprotection of the hindered neopentyl secondary C(11) TBS ether 
(Scheme 2.17).  The TBS ether (+)-2.56 was first treated with TBAF at room 
temperature, which resulted in hydrolysis of the Teoc carbamate. Subsequent warming 
the reaction mixture to 50 °C then led to selective removal of the C(11) TBS group in an 
overall yield of 79%. Oxidation with Dess-Martin periodinane35 provided ketone (–)-2.57 
in 87% yield.  
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Scheme 2.17. Late-Stage Selective Deprotection/Oxidation Sequence 
 
 
2.10.2 Global Deprotection of (–)-2.57: Completion of the First Total Synthesis of (–
)-Irciniastatin B (2.2) 
 We had predicted tetrahydropyranone (–)-2.57 to be very sensitive to both basic 
and acidic conditions; therefore prudent selection of mild reagents would be required. 
Global deprotection was first attempted with the mild Lewis acid MgBr2 to remove both 
pairs of protecting groups in a single operation (Scheme 2.18).36 One DMB ether and 
both SEM ethers proceeded to undergo hydrolysis to furnish mono-DMB ether 2.58. The 
chemoselectivity of DMB hydrolysis was not determined; however, DMB ethers ortho to 
lactones should be more labile due to neighboring group effect. Since treatment with a 
Lewis acid did not provide the desired natural product, a two-stage deprotection sequence 
would be required. Unfortunately, attempts to remove the final DMB ether with DDQ 
resulted in decomposition. On the other hand, when (–)-2.57 was treated with DDQ first, 
bis-phenol 2.59 was isolated cleanly. However, hydrolysis of the SEM ethers with mild 
basic fluoride reagents, TAS-F18,19 or TBAF resulted in a complex mixture. This 
undesired result highlights the heightened base sensitivity of tetrahydropyranone (–)-
2.57, compared to the late-stage intermediates in previous (+)-irciniastatin A (2.1) 
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Scheme 2.18. Attempted Global Deprotection of (–)-2.57 
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 Ultimately, we discovered that treatment of ketone (–)-2.57 with DDQ followed 
by a premixed solution of MgBr2, n-butanethiol, and nitromethane37 in Et2O furnished   
(–)-irciniastatin B (2.2) in 78% yield over two steps (Scheme 2.19). Pleasingly, the 
spectral data of totally synthetic (–)-irciniastatin B (2.2) was identical in all respects with 
the spectral data kindly provided to us by Pettit and coworkers.15 
Scheme 2.19. Global Deprotection of (–)-2.57 and Completion of (–)-Irciniastatin B (2.2) 
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2.11 Structural Confirmation of (–)-Irciniastatin B (2.2) by Chemical Conversion to 
(+)-Irciniastatin A (2.1) and epi-C(11)-Irciniastatin A (2.60) 
To verify the structural relationship of (–)-irciniastatin B (2.2) with (+)-
irciniastatin A (2.1), we carried out a chemical interconversion of 2.2 to 2.1 (Scheme 
2.20). To this end, (–)-irciniastatin B (2.2) was treated with NaBH4, which resulted in a 
mixture (1:1) of (+)-irciniastatin A 2.1 and epi-C(11)-irciniastatin A (2.60). The two 
diastereomers were separated via preparative TLC, and the spectral data of the faster 
moving diastereomer (TLC) proved to be identical in all respects with the spectral data of 
(+)-irciniastatin A (i.e., 1H, 13C NMR and HRMS), thereby confirming the structural 
relationship of (+)-irciniastatin A (2.1) and (–)-irciniastatin B (2.2). 
Scheme 2.20. Structural Confirmation of (–)-Irciniastatin B (2.1) by Chemical 
Conversion to (+)-Irciniastatin A (2.1)  
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2.12 Summary 
In summary, the first total synthesis of (–)-irciniastatin B (2.2) has been achieved 
with a longest linear sequence of 23 steps. The central features of this synthetic venture 
entailed a modified protecting group strategy that is amenable to scalable synthesis, and a 
late stage selective deprotection and oxidation sequence. Importantly, the structural 
relationship of the two metabolites has been confirmed via chemical conversion of (–)-
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irciniastatin B (2.2) to (+)-irciniastatin A (2.1) and the corresponding C(11) epimer 
(2.60). Importantly, the successful synthesis leading to (–)-irciniastatin B (2.2) now holds 
the promise for elaboration of C(11)-irciniastatin analogues. The design and synthesis of 
these analogues will be outlined in Chapter 3.  
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CHAPTER 3 Design and Synthesis of Irciniastatin Analogues 
3.1 Synthesis of Irciniastatin Analogues via Modification of Late-Stage Alcohol (–)-
3.4 and Ketone (–)-3.5 
Initial studies revealed that (–)-irciniastatin B (3.2) is 10-fold more cytotoxic 
compared to (+)-irciniastatin A (3.1) against pancreas, breast, and central nervous system 
cancer cell lines (Figure 3.1).1 Subsequent analogue studies conducted by the Schering-
Plough group revealed that C(11)-deoxy-irciniastatin A (3.3)2 is also up to 10-fold more 
active than (+)-irciniastatin A (3.1) against the variety of cancer cell lines tested. Taken 
together, the C(11) position in the irciniastatins would appear to play a critical role in 
irciniastatin’s biological mode of action. 
Figure 3.1. Natural and Unnatural C(11)-Irciniastatin Derivatives 
 
 
 
We therefore set out to modify late-stage synthetic intermediates, alcohol (–)-3.4 
and ketone (–)-3.5,3,4 to construct a small series of C(11)-irciniastatin analogues (Scheme 
3.1), with the expectation of possibly identifying an even more cytotoxic compound. We 
hypothesized the introduction of less polar substituents would improve the cytotoxic 
activity. Important in the synthesis of these analogues was the observed chemosynthetic 
strategy that led to the total synthesis of (–)-irciniastatin B (3.2). However, challenges to 
accessing C(11)-irciniastatin analogues remain, including limited reactivity of the 
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sterically hindered alcohol and ketone as well as the highly sensitive moieties present in 
both (–)-3.4 and (–)-3.5. Therefore, the analogues were carefully designed such that they 
can be synthesized under mild reaction conditions.  
Scheme 3.1. Synthetic Strategy to C(11)-Irciniastatin Analogues 
 
 
 
 
 
 
 
 
 
At the outset, our SAR studies focused on lowering the hydrophilicity of the 
C(11) substituent, and in particular removing the hydrogen-bond donating ability of the 
C(11) substituent (Schemes 3.2 and 3.3). Alcohol (–)-3.4 was capped with an acetate 
moiety in 87% yield. The two-stage global deprotection furnished C(11)-OAc-
irciniastatin A (+)-3.7 in 75% yield over the 2 steps. Benzoyl protection of alcohol (–)-
3.4 successfully provided the corresponding benzoate in 55% yield. Removal of the 
protecting groups then furnished C(11)-OBz-irciniastatin A (–)-3.6 in 50% yield over the 
2 steps.  
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A common strategy in medicinal chemistry is the addition of a fluorine substituent 
to enhance metabolic stability.5 We therefore proposed the synthesis of epi-C(11)-fluoro-
irciniastatin A 3.8. To this end, treatment of alcohol (–)-3.4 with diethylamino-
sulfurtrifluoride (DAST) resulted in the introduction of fluorine with inversion of 
stereochemistry.6 Future work includes hydrolysis of the remaining protecting groups to 
complete construction of analogue 3.8. 
Scheme 3.2. Synthesis of C(11)-Irciniastatin A Analogues from Alcohol (–)-3.4 
 
 
 
 
 
The congener, C(11)-exomethylene-irciniastatin B (+)-3.9, was constructed via 
Wittig methenylation7 of ketone (–)-3.5,  followed by global deprotection (Scheme 3.3). 
We envisioned that the exomethylene analogue would be an excellent bioisostere of the 
ketone since they bear a similar geometry and also further increases the hydrophobicity 
of the C(11) position, which should result in higher cytotoxicity.     
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Scheme 3.3. Synthesis of C(11)-Irciniastatin B Analogue from ketone (–)-3.5 
 
 
 
3.2 Progress Toward Disubstituted Irciniastatin Analogues 
 To simplify the synthetic route to cytotoxic irciniastatin analogues, we proposed 
the construction of disubstituted pyran analogues 3.10 (Scheme 3.4). Since removal of 
the C(11) substituent enhances cytotoxicity,2 we sought to remove the gem-dimethyl 
group along with the C(11) substitution from the tetrahydropyran core. We proposed to 
target both trans and cis analogues 3.10, which would derive from the unions of acid (–)-
3.11,4,8 aldehyde 3.12,3,4 and disubstituted pyrans 3.13. Epoxides 3.14 would be utilized 
as the cyclization precursors to generate the desired pyran intermediates 3.13 via a 6-exo-
tet-cyclization pathway as employed in our syntheses of (+)-irciniastatin A (3.1) and (–)-
irciniastatin B (3.2).3,4,8  
Scheme 3.4. Retrosynthetic Analysis of Disubstituted Irciniastatin Analogues 3.10 
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 Synthesis of this novel analogue began with asymmetric epoxidation of known 
allylic alcohol 3.15,9 employing the Sharpless protocol.10 After column chromatography, 
the resulting epoxy alcohol 3.16 was contaminated with (–)-DIPT. The mixture was then 
subjected to a three-step sequence to obtain methyl ester (+)-3.17: oxidation to the 
corresponding acid in a two-step sequence,11,12 followed by methylation. Only a single 
purification step was required after the methylation step to obtain (+)-3.17 in 59% yield 
over the 4 steps. Removal of the primary TBS ether to furnish alcohol (+)-3.18 occurred 
without event. Importantly, no pyran byproduct was observed under the acidic conditions 
employed. The absence of substitution in (+)-3.18 raised the activation barrier to the 
cyclization pathway. 
Scheme 3.5. Synthesis of Alcohol (+)-3.18 
 
 
 
 
 Future plans to complete the synthesis of disubstituted pyran analogues 3.10 are 
outlined in Scheme 3.6. Primary alcohol (+)-3.18 will be oxidized to aldehyde 3.19. 
Aldol union with 2-butanone, followed by acid-mediated cyclization will then furnish a 
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elaboration following our irciniastatin B synthetic route3,4 will complete the synthesis of 
disubstituted pyran analogues trans-3.10 and cis-3.10.  
Scheme 3.6. Synthetic Plan to Construction of Analogues 3.10 
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Chapter 4. Experimental Information 
4.1 Materials and Methods 
Reactions were carried out in flame-dried or oven dried glassware under a 
nitrogen atmosphere. Anhydrous diethyl ether (Et2O), tetrahydrofuran (THF), 
dichloromethane (CH2Cl2) and toluene were obtained from a Pure Solv PS-400 solvent 
purification system. Triethylamine, diisopropylethylamine and pyridine were freshly 
distilled from calcium hydride under a nitrogen atmosphere. All chemicals were 
purchased from Aldrich, Acros or TCI. Reactions were magnetically stirred unless stated 
otherwise and monitored by thin layer chromatography (TLC) with 0.25 mm Silacycle 
pre-coated silica gel plates. Silica gel chromatography was performed utilizing ACS 
grade solvents and silica gel from either Silacycle or Sorbent Technologies.  
Infrared spectra were obtained either neat or as a thin film using a Jasco FT/IR-480 plus 
spectrometer. Optical rotations were obtained using a Jasco P2000 polarimeter. All 
melting points were obtained on a Thomas-Hoover apparatus and are uncorrected. 1H 
NMR spectra (500 MHz field strength) and 13C NMR spectra (125 MHz field strength) 
were obtained on a Bruker Avance III 500 MHz spectrometer with dual inverse probe or 
a 5mm DCH cyroprobe or a Bruker Avance III cryomagnet (500MHZ/52mm) with a 5 
mm dual cryoprobe. Chemical shifts are reported relative to chloroform (δ 7.26) or 
methanol (δ 3.31) or benzene (δ 7.16) for 1H NMR spectra and chloroform (δ 77.23) or 
methanol (δ 49.15) or benzene (δ 128.06) for 13C spectra. High-resolution mass spectra 
(HRMS) were measured at the University of Pennsylvania on either a Waters LC-TOF 
mass spectrometer (model LCT-XE Premier) or a Waters GCT Premier Spectrometer. 
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4.2 Detailed Experimental Procedures 
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Tetrahydropyrans (+)-3.8 and (–)-3.9: (–)-DIP-Cl was weighed into a round bottom 
flask in a glovebox and placed under vacuum for 25 min to remove residual HCl. To a 
solution of (–)-DIP-Cl (950 mg, 2.96 mmol, 2.01 equiv) in ether (9.6 mL) at – 78 °C was 
added freshly distilled triethylamine (0.61 mL, 4.41 mmol, 3.0 equiv) dropwise over 5 
min. Butanone, freshly distilled from CaSO4 (0.26 mL, 2.96 mmol, 2.01 equiv) was 
added to the reaction solution dropwise over 5 minutes. The reaction mixture 
immediately becomes cloudy white upon addition of the first drop of butanone. The 
boron enolate solution was stirred for 2 h. Next, aldehyde (+)-2.34 (485.7 mg, 1.47 
mmol, azeotroped in benzene 3x, placed under high vacuum overnight) as a solution in 
ether (9.6 mL) was added to the reaction via syringe pump over 30 min. The aldehyde 
flask was washed with additional ether (5.0 mL) and added to reaction mixture via 
syringe pump over 30 min. The reaction solution was allowed to stir for 4 h at –78 °C. 
The reaction vessel was warmed slowly to –40 °C over 45 min and held at this 
temperature for 12 h. The reaction vessel was then warmed to 0 °C and quenched with a 
1:1:1 solution (23 mL) of pH 7 buffer, methanol, and hydrogen peroxide (35% aq. 
solution) and stirred for 1 h. The remaining peroxides were quenched with a saturated 
solution of sodium thiosulfate. The aqueous phase was extracted with EtOAc  (3x 20 
mL). The combined organic phases were further washed with a saturated solution of 
NaHCO3 (1x) and brine (1x). The resulting organic phase was dried over MgSO4, filtered 
∗
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O
CO2Me
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∗
O
O
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(+)-2.38 (–)-2.39
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and concentrated in vacuo. The resultant oil was purified via flash chromatography on 
SiO2 (10% to 15% to 20% EtOAc: hexanes) to furnish aldol product 2.9 (~224 mg, 0.56 
mmol, ~38% yield, 6:1 mixture of diastereomers) and dioxaborninane 2.35 (~379.8 mg, 
0.67 mmol, ~46% yield). 
 To a solution of mixture of diastereomers 2.9 (6:1) (224 mg, 0.56 mmol) in CH2Cl2 (11.2 
mL) was added (R)-CSA (25.5 mg, 0.11 mmol, 0.2 equiv). The reaction mixture was 
stirred for 2 h. The reaction mixture was then quenched with a saturated solution of 
NaHCO3 and extracted with CH2Cl2 (3 x 15 mL). The combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. The crude mixture was purified 
via flash chromatography on SiO2 (10% to 15% to 20% EtOAc: hexanes) to furnish 
tetrahydropyran (+)-2.38 (196.3 mg, 0.49 mmol, 33% over 2 steps) and (–)-2.39 (30.0 
mg, 0.07 mmol, 5.0% over 2 steps). 1H and 13C NMR spectral data was in complete 
agreement with the spectral data previously reported.1 
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vacuum for 25 min to remove residual HCl. To a solution of (–)-DIP-Cl (127.9 mg, 0.40 
mmol, 1.8 equiv) in ether (1.4 mL) at – 78 °C was added freshly distilled triethylamine 
(0.09 mL, 0.66 mmol, 3.0 equiv) dropwise over 5 min. Butanone, distilled from CaSO4 
(0.04 mL, 0.44 mmol, 2.0 equiv, distilled over CaSO4) was added to the reaction solution 
dropwise over 5 minutes. The reaction mixture immediately becomes cloudy white upon 
addition of the first drop of butanone. The boron enolate solution was stirred for 2 h, 
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next, aldehyde (+)-2.34 (71.1 mg, 0.22 mmol, azeotroped in benzene 3x, placed under 
high vacuum overnight) in a solution of ether (1.4 mL) was added to the reaction via 
syringe pump over 1 h. The aldehyde flask was washed with additional ether (1.4 mL) 
and added to reaction mixture via syringe pump over 30 min. The reaction solution was 
allowed to stir for 22 h at –78 °C. The reaction mixture was quenched with 2:1 solution 
(2.0 mL) of MeOH and pH 7 buffer solution, followed by addition of m-CPBA (300 mg, 
1.32 mmol, 6 equiv). The reaction vessel was warmed to –65 °C and allowed to stir 
overnight. The reaction mixture was cooled to –78 °C and the remaining peroxides were 
quenched with dimethylsulfide (1.0 mL). The reaction mixture was warmed to rt and 
stirred for 30 min. The aqueous phase was extracted with EtOAc  (3 x 10 mL). The 
combined organic phases were further washed with a solution of K2CO3 (0.1 N) (4x) and 
brine (1x). The resulting organic phase was dried over MgSO4, filtered and concentrated 
in vacuo. The resultant crude oil was purified via flash chromatography on SiO2 (10% to 
15% to 20% EtOAc: hexanes) to furnish aldol product 2.9 (~66.0 mg, 0.164 mmol, 75% 
yield, 1:1 dr).  
 
 
 
Tetrahydropyran (–)-2.37: To a solution of dioxaborinane 2.35 (170 mg, 0.46 mmol) in 
CH2Cl2 (6.2 mL) was added (R)-CSA (14.4 mg, 0.062 mmol, 0.13 equiv). The reaction 
mixture was stirred overnight. Starting 2.35 was still observed by TLC (20% EtOAc: 
hexanes). (R)-CSA (51 mg, 0.22, 0.50 equiv) was added and the reaction was stirred for 
O O
∗ ∗
OTBSB O
OMe
O (R)-CSA
CH2Cl2
*
O*
HO
CO2Me
OH
OTBS
HH
Single Isomer
2.35 (–)-2.37
!78!
10 h. The reaction mixture was quenched with a saturated solution of NaHCO3 and 
extracted with CH2Cl2 (3 x 15 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude mixture was purified via flash 
chromatography on SiO2 (10% to 15% to 20% to 25% to 30% EtOAc: hexanes) to furnish 
tetrahydropyran (–)-2.37 (44.0 mg, 0.109 mmol, 24%, single isomer) as a colorless  solid: 
Melting Point= 61.0-64.0 °C;  –39.8 (c 0.18 CH2Cl2); IR (neat) 3436, 2956, 2857, 
1741, 1465, 1389, 1254, 1094 cm-1; 1H NMR (500 MHz, CDCl3) δ 4.22 (d, J = 2.0 Hz, 1 
H) 4.06 (ddd, J = 2.4, 3.8, 11.9 Hz, 1 H), 3.96 (dd, J = 2.2, 11.1 Hz, 1 H), 3.79 (s, 3 H), 
3.71 (m, 1 H), 3.54 (ap t, J = 2.4 Hz, 1 H), 2.50 (bs, 1 H), 2.03 (ddd, J = 2.4, 12.1, 14.0 
Hz, 1 H), 1.65 (ddd, J = 2.8, 10.9, 14.2 Hz, 1 H), 1.56-1.43 (m, 3 H), 1.35 (ddd, J = 2.7, 
2.7, 13.8 Hz, 1 H), 0.94 (t, J = 7.3 Hz, 3 H), 0.90 (s, 9 H), 0.88 (s, 3 H), 0.80 (s, 3 H), 
0.04 (s, 3 H), 0.03 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 173.3, 76.2, 75.0, 74.2, 73.5, 
71.0, 52.8, 37.5, 34.7, 30.7, 30.0, 29.9, 26.1, 23.8, 19.7, 18.3, 10.6, –4.3, 4.7; HRMS 
(ES+) m/z 405.2668 [(M+H)+; calcd for C20H41O6Si: 405.2672]. 
 
 
Bis-DMB ether 2.47: To a solution of bis-phenol 2.25 (519 mg, 2.043 mmol) in acetone 
(25.0 mL) was added K2CO3 (1.03 g, 7.452 mmol, 3.7 equiv) followed by dropwise 
addition of a solution of 3,4-dimethoxybenzylbromide2 (2.0 mL, 2.2 M in acetone, 2.2 
equiv). The yellow reaction mixture was stirred for 24 h and quenched with H2O (20 
mL). The layers were separated and the aqueous layer was extracted with EtOAc (3 x 20 
mL). The combined organic layers were dried over MgSO4, filtered and concentrated in 
vacuo. The crude mixture was purified via flash chromatography on SiO2 (40% to 50% 
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EtOAc: hexanes) to provide 2.47 (850 mg, 1.532 mmol, 75%) as a colorless solid: 
Melting point= 102.0-103.0 °C; IR (neat) 2947, 1732, 1594, 1515, 1459, 1264, 1152, 
1025 cm-1; 1H NMR (500 MHz, CDCl3) 6.97-6.81 (m, 6 H), 6.52 (s, 1 H), 4.99 (s, 2 H), 
4.95 (s, 2 H), 3.89 (s, 3 H), 3.88 (s, 3 H), 3.88 (s, 3 H), 3.87 (s, 3 H), 3.83 (s, 3 H), 3.69 
(s, 2 H), 3.67 (s, 3 H), 2.14 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 171.2, 158.7, 155.2, 
149.4, 149.3, 149.1, 148.9, 132.7, 129.6, 129.4, 120.0, 119.7, 119.6, 117.8, 111.3, 111.1, 
110.9, 110.1, 98.3, 71.2, 70.7, 56.1, 56.1, 56.1, 56.0, 52.2, 36.2, 11.7; HRMS (ES+) m/z 
577.2047 [(M+Na)+; calcd for C30H34O10Na: 577.2050]. 
 
 
Aldehyde 2.48: To a solution of bis-DMB ether 2.47 (850 mg, 1.53 mmol) in CH2Cl2 
(15.3 mL) was cooled to –78 °C and DIBAL-H (2.1 mL, 1.0 M in hexanes, 1.4 equiv) 
was added over 20 min via syringe pump. The reaction mixture was allowed to stir for an 
additional 5 min before it was quenched by the addition of MeOH (7.0 mL) and was 
warmed to room temperature, then diluted with EtOAc (2 mL) and a saturated aq. 
solution of Rochelle’s salt (2 mL). The biphasic reaction mixture was allowed to stir for 1 
h at room temperature to allow the organic layer to transition from cloudy to clear. The 
layers were separated and the aqueous layer was extracted with EtOAc (3 x 3 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The 
crude mixture was purified via flash chromatography on SiO2 (40% to 50% EtOAc: 
hexanes) to provide 2.48 (697 mg, 1.33 mmol, 87%) as a colorless solid: Melting point= 
122.5-124.0 °C; IR (neat) 2944, 2838, 2726, 1722, 1594, 1515, 1459, 1265, 1153, 1030 
cm-1; 1H NMR (500 MHz, CDCl3) 9.65 (t, J = 1.8 Hz, 1 H), 6.97 (d, J = 1.7 Hz, 1 H), 
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6.94-6.83 (m, 5 H), 6.55 (s, 1 H), 5.02 (s, 2 H), 4.97 (s, 2 H), 3.90 (s, 3 H), 3.89 (s, 9 H), 
3.84 (s, 3 H), 3.68 (d, J = 1.6 Hz, 2 H), 2.10 (s, 3 H); 13C NMR (125 MHz, MeOD) δ 
198.6, 168.7, 158.9, 155.4, 149.4, 149.4, 149.2, 149.0, 131.0, 129.4, 129.2, 120.1, 119.8, 
119.7, 118.0, 111.3, 111.1, 110.0, 110.7, 98.5, 71.2, 70.7, 56.3, 56.1, 56.1, 56.1, 52.3, 
46.1, 11.9; HRMS (ES+) m/z 525.2141 [(M+Na)+; calcd for C29H33O9: 525.2125]. 
 
 
 
β-Hydroxy Ketone (+)-2.49: To a solution of ketone (+)-2.6 (114 mg, 0.274 mmol, 
azeotroped in benzene 3x, placed under high vacuum overnight) in CH2Cl2 (1.35 mL) 
was cooled to –78 °C and Cl2BPh (0.05 mL, 0.383 mmol, 1.4 equiv) was added dropwise. 
After 20 min, i-Pr2NEt (0.10 mL, 0.574 mmol, 2.1 equiv) was introduced dropwise. After 
1 h, the reaction mixture was warmed to 0 °C, where it was stirred for 1 h then cooled 
back down to –78 °C. Aldehyde 2.48 (205 mg, 0.391 mmol, 1.5 equiv) was dissolved in 
CH2Cl2 (0.7 mL) and was added to the boron enolate solution at –78 °C over 15 min via 
syringe pump. After 4 h at –78 °C, the reaction mixture was quenched with a 1:1 mixture 
of MeOH and pH 7 buffer (4 mL). While warming to 0 °C, pH 8 buffer solution was 
added to neutralize the reaction mixture to pH 7 and the biphasic mixture was stirred for 
1 h at 0 °C. The layers were separated and the aqueous layer was extracted with CH2Cl2 
(3 x 5 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuo. The resulting crude mixture was purified via flash 
chromatography on deactivated SiO2 (2% v/v triethylamine, 7.5% to 10% EtOAc: 
DMBO
DMBO
OCO2Me
O
OTBS
H
H
OMe
OH
MeO
O
!81!
CH2Cl2) to provide a mixture (ca. 10:1) of β-hydroxy ketone (+)-2.49 and corresponding 
lactone (176 mg, 0.192 mmol, 70%) as a colorless foam: 
€ 
[α]D20 +29.8 (c 0.68 CHCl3); IR 
(neat) 3417, 2924, 2855, 1719, 1590, 1516, 1461, 1264, 1154 cm-1; 1H NMR (500 MHz, 
CDCl3) Major: δ 6.95-6.91 (m, 3 H), 6.88-6.82 (m, 3 H), 6.49 (s, 1 H), 5.02-4.97 (m, 2 
H), 4.95 (s, 2 H), 4.10 (dd, J = 5.3, 10.9 Hz, 1 H), 4.06 (dd, J = 2.9, 9.1 Hz, 1 H), 4.06-
4.03 (m, 1 H), 3.94 (d, J = 6.3 Hz, 1 H), 3.89 (s, 3 H), 3.89 (s, 3 H), 3.88 (s, 3 H), 3.88 (s, 
3 H), 3.85 (s, 3 H), 3.72 (s, 3 H), 3.64 (dd, J = 3.7, 7.7 Hz, 1 H), 3.46 (d, J = 5.6 Hz, 1 H), 
3.41 (s, 3 H), 3.06 (dd, J = 9.4, 16.0 Hz, 1 H), 2.87 (dd, J = 3.4, 14.3 Hz, 1 H), 2.68 (dq, J 
= 7.1, 5.4 Hz, 1 H), 2.62 (dd, J = 10.1, 14.1 Hz, 1 H), 2.54 (dd, J = 3.0, 16.4 Hz, 1 H), 
2.20 (s, 3 H), 1.96 (ddd, J = 3.9, 6.0, 13.9 Hz, 1 H), 1.58 (ddd, J = 5.0, 7.9, 13.3 Hz, 1 H), 
1.21 (d , J = 6.9 Hz, 3 H), 0.96 (s, 3 H), 0.90 (s, 9 H), 0.85 (s, 3 H), 0.04 (s, 3 H), 0.04 (s, 
3 H); Distinct peaks from minor byproduct: δ 6.54 (s), 5.16 (dab, J = 12.2 Hz), 5.10 (dab, 
J = 11.8 Hz), 1.33 (d, J = 7.0 Hz); 13C NMR (125 MHz, CDCl3) δ 212.5, 171.5, 170.7, 
159.0, 155.2, 149.4, 149.3, 149.1, 148.9, 137.1, 129.5, 129.5, 120.0, 119.8, 119.3, 117.9, 
111.3, 111.1, 110.8, 110.7, 97.6,  82.3, 77.4,  76.7, 73.0, 71.6, 71.2, 70.6, 70.1, 58.8, 56.1, 
56.1, 56.1, 56.1, 53.2, 52.6, 52.1, 42.4, 38.0, 35.8, 30.0, 26.0, 24.9, 18.2, 11.8, 11.4, –4.3, 
–4.9; HRMS (ES+) m/z 963.4525 [(M+Na)+; calcd for C50H72O15SiNa: 963.4538]. 
 
 
 
Acid (+)-2.52: To a solution of β-hydroxy ketone (+)-2.49 (203 mg, 0.215 mmol) in THF 
(2.20 mL) and MeOH (0.73 mL) cooled to –78 °C was added a solution of Et2BOMe 
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(0.31 mL, 1M in THF, 1.4 equiv). The reaction mixture was stirred for 25 min before 
NaBH4 (45 mg, 1.189 mmol, 5.4 equiv) was added. After 5.5 h, the reaction was warmed 
to 0 °C and quenched with a 1:1 mixture of MeOH and pH 7 buffer (4.0 mL) followed by 
the addition of m-CPBA (0.330 g, 1.31 mmol, 6.0 equiv) portion-wise. After 30 min, the 
reaction mixture was warmed to room temperature, and dimethylsulfide was added 
slowly to quench remaining peroxides. After 10 min, aq. solution of K2CO3 (5 mL, 0.1 N) 
was added and the layers were separated. The aqueous layer was extracted with EtOAc (3 
x 5 mL). The combined organic layers were washed with brine, then dried over MgSO4, 
filtered and concentrated in vacuo. The crude mixture was purified via flash 
chromatography (50% to 60% EtOAc: hexanes then flushed with 10% MeOH: EtOAc) to 
provide a mixture (ca. 8:1) of diol 2.50 and lactone 2.51 (183 mg).  
The mixture of diol 2.50 and lactone 2.51 was dissolved in MeOH (10.0 mL) and cooled 
to 0 °C followed by the addition of H2O (70 µL, 3.889 mmol, 20.0 equiv) and LiOH (191 
mg, 7.975 mmol, 40.0 equiv). The reaction mixture was allowed to warm to room 
temperature and after 35 h, the reaction mixture was quenched with 50% aqueous acetic 
acid solution (5 mL). Brine (6 mL) and H2O (2 mL) were added and the layers were 
separated. The aqueous layer was extracted with EtOAc (5 x 15 mL). The combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo. Crude mixture 
was purified via column chromatography on SiO2 (0.1% acetic acid in 60% EtOAc: 
hexanes to 0.1% acetic acid in 80% EtOAc: hexanes) to provide acid (+)-2.52 (136 mg, 
0.152 mmol, 69% over two steps) as a colorless foam: 
€ 
[α]D20 +22.4 (c 0.9 CHCl3); IR 
(neat) 3522, 3058, 2937, 2862, 2862, 1712, 1590, 1515, 1461, 1381, 1261, 1153, 1090 
!83!
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.33 (d, J = 1.7 Hz, 1 H), 6.92 (m, 3 H), 6.86 (d, J = 
8.0 Hz, 1 H), 6.82 (d, J = 8.3 Hz, 1 H), 6.51 (s, 1 H), 5.15 (dab, J = 11.8 Hz, 1 H), 5.09 
(dab J = 12.2 Hz, 1 H), 4.99 (s, 2 H), 4.33 (ddd, J = 2.3, 5.5, 8.0 Hz, 1 H) 4.19 (dd, J = 
6.0, 11.7 Hz, 1 H), 4.13 (m, 1 H), 3.91 (s, 3 H), 3.89 (s, 3 H), 3.88 (s, 3 H), 3.86 (s, 3 H), 
3.85 (d, J = 4.1 Hz, 1 H), 3.60 (d, J = 12.3 Hz, 1 H), 3.57 (dd, J = 4.0, 7.6 Hz, 1 H) 3.41 
(s, 3 H), 3.02 (dd, J = 2.7, 17.2 Hz, 1 H), 2.88 (dd, J = 12.3, 16.4 Hz, 1 H), 2.11 (s, 3 H), 
2.08 (m, 1 H), 2.01-1.93 (m, 2 H), 1.66 (ddd, J = 5.1, 8.0, 13.6 Hz, 1 H), 1.56 (app d, J = 
14 Hz, 1 H), 1.07 (d, J = 6.9 Hz, 3 H), 0.94 (s, 3 H), 0.89 (s, 9 H), 0.87 (s, 3 H), 0.05 (s, 3 
H), 0.04 (s, 3 H); 13C NMR (125 MHz, CDCl3) δ 172.3, 164.4, 161.4, 160.4, 149.5, 
149.4, 149.2, 148.7, 142.2, 129.6, 128.9, 120.2, 119.0, 116.3, 111.3, 111.0, 110.9, 110.7, 
107.7, 97.9, 82.0, 81.8, 79.0, 72.6, 71.6, 71.1, 70.5, 69.8, 58.7, 56.2, 56.1, 41.5, 38.7, 
33.1, 30.6, 29.4, 26.0, 25.0, 18.2, 11.3, 9.5, –4..2, –4.8; HRMS (ES+) m/z 919.4287 
[(M+Na)+; calcd for C48H68O14SiNa: 919.4276]. 
 
 
 
N,O-aminal (+)-S1: A solution of acid (+)-2.52 (116 mg, 0.129 mmol) in freshly 
distilled acetone (6.6 mL, distilled from CaSO4) was cooled to 0 °C followed by the 
dropwise addition of i-Pr2NEt (0.05 mL, 0.287 mmol, 2.2 equiv) and a solution of 
isobutylchloroformate (0.50 mL, 0.64 M in acetone, 2.4 equiv). After 1 h, a solution of 
NaN3 (0.85 mL, 0.78 M in H2O, 5 equiv) was added to the reaction mixture dropwise. 
After an additional 20 min at 0 °C, the reaction mixture was diluted with cold H2O (15 
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mL). The layers were separated and the aqueous layer was extracted with cold EtOAc (3 
x 10 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuo. The crude acyl azide was azeotroped (benzene x3) and placed 
under high vacuum (~0.1 mmHg) for 30 min. The acyl azide was dissolved in toluene 
(6.6 mL) and reaction flask was fitted with a reflux condenser and heated to 80 °C. After 
45 min, 2-TMS-ethanol (0.67 mL, 4.674 mmol, 36.2 equiv) was added via syringe 
through the top of the condenser. After 5 h at 80 °C, the reaction mixture was cooled to 
room temperature and concentrated in vacuo. The crude mixture was purified via flash 
chromatography on SiO2 (40% to 50% EtOAc: hexanes) to provide N,O-aminal (+)-S1 
(90 mg, 0.087 mmol, 67%) as a colorless foam: 
€ 
[α]D20 +3.7 (c 0.5, CHCl3); IR (neat) 3502, 
3340, 2947, 2859, 1713, 1589, 1515, 1462, 1253, 1151, 1078, 1034, 840 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 7.34 (d, J = 1.8 Hz, 1 H), 6.93 (m, 3 H), 6.87 (d, J = 8.0 Hz, 1 H), 
6.82 (d, J = 8.3 Hz, 1 H), 6.52 (s, 1 H), 5.38, (d, J = 8.8 Hz, 1 H), 5.16 (dab, J = 12.0, 1 
H), 5.09 (dab, J = 11.9 Hz, 1 H), 4.99 (s, 2H), 4.89 (d, J = 9.6 Hz, 1 H), 4.31 (ddd, J = 
2.2, 6.6, 10.5 Hz, 1 H), 4.19 (ddd, J = 8.3, 10.3, 18.2 Hz, 1 H), 4.12 (m 2 H), 3.98 (d, J = 
9.1 Hz, 1 H), 3.92 (s, 3 H), 3.89 (s, 3 H), 3.88 (s, 3 H), 3.87 (m, 1 H), 3.86 (s, 3 H), 3.66 
(s, 1 H), 3.62 (d, J =11.5 Hz, 1 H), 3.56 (m, 1 H), 3.35 (s, 3 H), 3.10 (app d, J = 16.5 Hz, 
1 H), 2.83 (dd, J = 12.1, 16.0 Hz, 1 H), 2.37 (m , 1 H), 2.12 (s, 3 H), 1.85 (m, 2 H), 1.45-
1.41 (m, 2 H), 1.11 (d, J = 6.9 Hz, 3 H), 0.10 (s, 3 H), 0.97 (t, J = 8.6 Hz, 2 H), 0.89 (s, 9 
H), 0.87 (s, 3 H), 0.04 (s, 3 H), 0.03 (s, 3 H), 0.01 (s, 9 H); 13C NMR (125 MHz, CDCl3) 
δ 163.7, 161.2, 160.3, 157.1, 149.6, 149.4, 149.2, 148.7, 142.2, 129.7, 129.0, 120.1, 
119.0, 116.2, 111.3, 111.0, 110.9, 110.8, 108.2, 97.9, 83.7, 83.6, 79.3, 77.4, 73.0, 72.7, 
71.1, 70.5, 63.7, 56.2, 56.1, 56.1, 55.8, 43.4, 38.0, 32.9, 31.1, 29.7, 26.1, 26.0, 18.1, 17.8, 
!85!
11.4, 10.1, –1.3, –4.4, –4.8. HRMS (ES+) m/z 1034.5088 [(M+Na)+; calcd for 
C53H81NO14Si2Na: 1034.5093]. 
 
 
 
SEM-ether (+)-2.53: A solution of N,O-aminal (+)-S1 (86 mg, 0.085 mmol) in THF (0.6 
mL) was cooled to 0 °C followed by the addition of i-Pr2NEt (0.13 mL, 0.746 mmol, 9 
equiv), SEMCl (0.09 mL, 0.509 mmol, 6 equiv), and TBAI (8 mg, 0.022 mmol, 0.2 
equiv). The reaction mixture was stirred at 0 °C for 15 min and was allowed to warm to 
room temperature and stirred for 23 h. The reaction mixture was quenched with a 
saturated aq. solution of NaHCO3 (1 mL). The aqueous layer was extracted with EtOAc 
(3 x 3 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuo. The crude mixture was purified via flash chromatography on SiO2 
(35% to 40% EtOAc: hexanes) to provide desired SEM ether (+)-2.53 (0.080 g, 0.070 
mmol, 82%) as a colorless foam: 
€ 
[α]D20  +31.6 (c 0.8, CHCl3); IR (neat) 3336, 2952, 2929, 
2858, 1716, 1593, 1518, 1464, 1264, 1249, 1160, 1078, 1027, 836 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.33 (d, J = 1.8 Hz, 1 H), 6.98-6.93 (m, 3 H), 6.88 (d, J = 8.7 Hz, 1 H), 
6.83 (d, J = 8.3 Hz, 1 H), 6.54 (s, 1 H), 5.60 (bd, J = 9.2 Hz, 1 H), 5.19 (dab, J = 11.7 Hz, 
1 H), 5.10 (dab, J = 11.6 Hz, 1 H), 4.98 (s, 2 H), 4.81 (bd, J = 7.9 Hz, 1 H), 4.69-4.59 (m, 
2 H), 4.26 (ddd, J = 2.3, 8.4, 11.4 Hz, 1 H), 4.17 (dd, J = 7.5, 10.5 Hz, 1 H), 4.10 (m, 1 
H), 3.98-3.94 (m, 2 H), 3.94 (s, 3 H), 3.93 (s, 3 H), 3.89 (s, 3 H), 3.88 (s, 3 H), 3.58 (dd, J 
= 4.2 Hz, 1 H), 3.54 -3.48 (m, 1 H), 3.44-3.39 (m, 1 H), 3.36 (s, 3 H), 3.34-3.27 (m, 2 H), 
DMBO
DMBO
OSEMO
O
O
OTBS
H
HNH
Teoc
OMe
!86!
2.65 (dd, J = 7.8, 16.0 Hz, 1 H), 2.47 (m, 1 H), 2.15 (s, 3 H), 2.04 (m, 1 H), 1.82 (ddd, J 
= 2.4, 9.5, 12.9 Hz, 1 H), 1.66 (m , 1 H), 1.51 (ddd, J = 3.9, 8.5, 14.2 Hz, 1 H), 1.13 (d, J 
= 7.1 Hz, 3 H), 0.98 (s, 3 H), 0.94 (m, 2 H), 0.90 (s, 9 H), 0.87 (s, 3 H), 0.85-0.77 (m, 1 
H), 0.71-0.65 (m, 1 H), 0.05 (s, 3 H), 0.04 (s, 3 H), 0.004 (s, 9 H), –0.13 (s, 9 H) ; 13C 
NMR (125 MHz, CDCl3) δ 163.6, 161.3, 160.4, 157.2, 149.6, 149.5, 149.3, 148.8, 142.2, 
129.7, 129.0, 120.2, 119.2, 116.3, 111.4, 111.2, 111.0, 110.9, 108.3, 98.0, 93.6, 84.4, 
79.4, 77.4, 75.0, 73.5, 71.2, 70.5, 67.6, 65.7, 63.6, 56.3, 56.2, 56.2, 56.1, 56.0, 39.3, 37.7, 
31.7, 29.9, 29.3, 26.3, 26.0, 18.2, 18.1, 17.9, 11.4, 9.9, –1.3, –1.4, –4.3, –4.8. high 
resolution mass spectrum (ES+) m/z 1164.5879 [(M+Na)+; calcd for C59H95NO15Si3Na: 
1164.5907]. 
 
 
Acid Chloride 2.55:3 To a solution of carboxylic acid (–)-2.3 (31 mg, 0.102 mmol) in 
CH2Cl2 was added a solution of pyridine (0.66 mL, 0.62 M in CH2Cl2, 4 equiv) and a 
solution of thionyl chloride (0.64 mL, 0.48 M in CH2Cl2, 3 equiv) and stirred at rt for 2 h. 
The resulting solution was concentrated under a stream of positive N2 then placed under 
vacuum (~0.1 mmHg). The crude mixture was dissolved in toluene (0.4 mL) and 
transferred to an oven-dried vial via cannula transfer (flask rinsed with 2 x 0.4 mL 
toluene). Crude acid chloride 2.55 was concentrated in vacuo, dissolved in THF (1.0 mL, 
0.1 M), and used in the next step without further purification. 
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Amide (+)-2.56: To a solution of carbamate (+)-2.53 (0.030 mg, 0.026 mmol) in THF 
(0.65 mL) cooled to –78 °C and added a solution of i-PrMgCl (55 µL, 2.0 M in THF, 4 
equiv) over 2 min. The yellow solution was stirred for 30 min at –78 °C then a solution of 
acid chloride 2.55 (1.0 mL, 0.1 M in THF, 3.9 equiv) was added dropwise over 20 min. 
After 2.5 h, the reaction mixture was quenched with a saturated aq. solution of NaHCO3 
(1.5 mL) and warmed to rt. The aqueous layer was extracted with EtOAc (3 x 2 mL) and 
the combined organic layers were washed with brine, then dried over MgSO4, filtered and 
concentrated in vacuo. The crude mixture was purified via flash chromatography on 
deactivated silica gel (1% v/v triethylamine, 25% to 30% EtOAc: hexanes) to furnish 
amide (+)-2.56 (27 mg, 0.019 mmol, 72%) as a white foam: 
€ 
[α]D20 +27.0 (c 0.3, CHCl3); 
IR (neat) 2928, 2856, 1716, 1593, 1518, 1464, 1250, 1160, 1083, 1029, 859, 837 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.34 (d, J = 1.9 Hz, 1 H), 6.97-6.93 (m, 3 H), 6.88 (d, J = 8.0 
Hz, 1 H), 6.83 (d, J = 8.2 Hz, 1 H), 6.54 (s, 1 H), 5.62 (d, J = 5.7 Hz, 1 H), 5.17 (d, J = 
4.4 Hz, 1 H), 5.16 (d, J = 12.7 Hz, 1 H), 5.10 (d, J = 11.9 Hz, 1 H), 4.98 (s, 2 H), 4.75 (s, 
1 H), 4.73 (s, 1 H), 4.67 (dd, J = 6.4, 12.7 Hz, 2 H), 4.59 (dd, J = 7.1, 25.3 Hz, 2 H), 4.35 
(m, 1 H), 4.32 (dd, J = 3.6, 6.8 Hz, 1 H), 4.30-4.25 (m, 2 H), 3.93 (s, 3 H), 3.91 (s, 3 H), 
3.90 (s, 3 H), 3.88 (s, 3 H), 3.83 (m, 1 H), 3.64 (m, 1 H), 3.58 (ddd, J = 1.6, 9.8, 13.1 Hz, 
2 H), 3.53 (m, 1 H), 3.47-3.38 (m, 2 H), 3.36 (s, 3 H), 3.31 (s, 3 H), 3.24 (dd, J = 1.8, 
17.7 Hz, 1 H), 3.20 (m, 1 H), 2.86 (dd, J = 12.4, 15.9 Hz, 1 H), 2.26 (m, 1 H), 2.25 (m, 1 
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H), 2.21 (s, 3 H), 2.05 (m, 1 H), 1.96 (ddd, J = 4.0, 4.0, 13.7 Hz, 1 H), 1.86 (m, 2 H), 1.73 
(s, 3 H), 1.70 (m, 1 H), 1.14 (d, J = 7.6 Hz, 3 H), 1.09 (dd J = 7.1, 9.2 Hz, 2 H), 0.92 (s, 3 
H), 0.90 (s, 9 H), 0.86 (s, 3 H), 0.84 (m, 2 H), 0.78 (ddd, J = 5.7, 11.6, 13.6 Hz, 1 H), 
0.66 (ddd, J = 5.5, 11.6, 13.6 Hz, 1 H), 0.06 (s, 3 H), 0.05 (s, 3 H), 0.05 (s, 9 H), –0.05 (s, 
9 H), –0.15 (s, 9 H) ; 13C NMR (125 MHz, CDCl3) δ 175.2, 163.9, 161.2, 160.4, 154.5, 
149.5, 149.4, 149.2, 142.9, 148.7 142.6, 129.7, 129.0, 120.2, 119.1, 116.4, 112.8, 111.2, 
111.0, 110.8, 110.7, 108.2, 97.7, 95.1, 94.1, 88.5, 81.1, 79.6,  77.4, 77.0, 75.9, 73.0, 71.2, 
70.4, 66.3, 66.0, 65.7, 58.4, 57.0, 56.2, 56.1, 56.1, 56.1, 39.8, 39.1, 38.8, 31.8, 31.1, 29.9, 
29.9, 26.1, 24.7, 23.1, 18.2, 18.2, 18.1, 17.7, 11.5, 9.8, –1.3, –1.4, –1.4,  –4.1,  –4.8.  
HRMS (ES+) m/z 1450.7513 [(M+Na)+; calcd for C73H121NO19Si4Na: 1450.7508]. 
 
 
 
Alcohol (–)-3.4: To a solution of amide (+)-2.56 (7.0 mg, 0.005 mmol) in THF (0.1 mL) 
was added a solution of TBAF (15 µL, 1 M in THF, 3.0 equiv). The yellow solution was 
stirred at rt for 1 h then warmed to 50 °C. After 19 h, additional TBAF (10 µL, 0.010 
mmol, 2.0 equiv) was added. The reaction mixture was stirred at 50 °C for an additional 
23 h, then cooled to rt, quenched with water and extracted with EtOAc (4 x 0.5 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The 
crude mixture was purified via flash chromatography on SiO2 (40% to 60% to 70% 
EtOAc: hexanes) to furnish alcohol (–)-3.4 (4.5 mg, 0.004 mmol, 79%) as a colorless oil: 
€ 
[α]D20 –3.2 (c 0.3, CHCl3); IR (neat) 3426, 2951, 2835, 1715, 1685, 1593, 1517, 1265, 
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1248, 1160, 1028 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.32 (d, J = 1.6 Hz, 1 H), 7.25 (d, 
J = 9.4 Hz, 1 H), 6.97-6.92 (m, 3 H), 6.87 (d, J = 8.8 Hz, 1 H), 6.83 (d, J = 8.0 Hz, 1 H), 
6.53 (s, 1 H), 5.13 (ABq, J = 11.7 Hz, 2 H), 5.09 (dd, J = 2.5, 5.6 Hz, 1 H), 4.98 (s, 2 H), 
4.83 (d, J = 6.6 Hz, 1 H), 4.77 (s, 1 H), 4.76 (s, 1 H), 4.70 (ABq, J = 5.5 Hz, 2 H), 4.60 
(d, J = 7.7 Hz, 1 H), 4.40 (d, J = 2.1 Hz, 1 H), 4.27 (ddd, J = 1.9, 7.8, 11.9 Hz, 1 H), 4.08 
(m, 1 H), 3.99 (m, 1 H), 3.93 (s, 3 H), 3.90 (s, 3 H), 3.89 (s, 3 H), 3.87 (s, 3 H), 3.74 (m, 
2 H), 3.67 (dd, J = 4.5, 4.5 Hz, 1 H), 3.58 (ddd, J = 6.5, 10.3, 10.3 Hz, 1 H), 3.50-3.43 
(m, 2 H), 3.37 (s, 3 H), 3.32 (s, 3 H), 3.27 (dd, J = 2.2, 16.7 Hz, 1 H), 2.65 (dd, J = 12.7, 
16.4 Hz, 1 H), 2.46 (m, 1 H), 2.37 (dd, J = 8.5, 14.5 Hz, 1 H), 2.19 (dd, J = 4.7, 14.8 Hz, 
1 H), 2.14 (s, 3 H), 2.10 (ddd, J = 2.6, 8.4, 8.4 Hz, 1 H), 2.01 (m, 1 H), 1.81 (ddd, J = 
2.54, 9.4, 13.5 Hz, 1 H), 1.73 (m, 1 H), 1.70 (s, 3 H), 1.56 (dd, J =4.7, 9.6 Hz, 1 H), 1.54 
(dd, J = 5.0, 9.3 Hz, 1 H), 1.15 (d, J = 6.7 Hz, 3 H), 1.00 (s, 3 H), 0.94 (s, 3 H), 0.91 (m, 
2 H), 0.85-0.79 (m, 1 H), 0.71-0.69 (m, 1 H), 0.01 (s, 9 H), –0.13 (s, 9 H); 13C NMR (125 
MHz, CDCl3) δ 171.2, 163.9, 161.3, 160.4, 149.5, 149.4, 149.2, 148.7, 142.4, 142.2, 
129.6, 128.9, 120.2, 119.2, 116.7, 113.0, 111.2, 111.0, 110.9, 110.7, 108.1, 97.7, 94.8, 
94.4, 81.8, 81.4, 79.6, 77.4, 75.5, 72.9, 71.1, 70.5, 68.0, 66.2, 65.6, 58.0, 56.3, 56.2, 56.2, 
56.1, 56.1, 39.2, 38.3, 37.3, 30.7, 30.0, 29.9, 29.5, 26.0, 22.9, 19.4, 18.2, 18.1, 11.4, 9.6, 
–1.2, –1.4; HRMS (ES+) m/z 1192.6072 [(M+Na)+; calcd for C61H95NO17Si2Na: 
1192.6036]. 
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Ketone (–)-2.57: To a solution of alcohol (–)-3.4 (3.5 mg, 0.003 mmol) in CH2Cl2 (0.05 
mL) was added NaHCO3 (4.2 mg, 16.6 equiv). The reaction mixture was cooled to 0 °C 
and Dess-Martin periodinane (6.0 mg, 0.015 mmol, 5.0 equiv) was added and the 
resulting mixture was stirred for 3 h. Reaction was quenched with a saturated aq. solution 
of NaHCO3 and extracted with EtOAc (4 x 0.5 mL). The combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. The crude mixture was purified 
via flash chromatography on SiO2 (40% to 50% EtOAc: hexanes) to furnish ketone        
(–)-2.57 (3.0 mg, 0.0026 mmol, 87%) as a colorless oil: 
€ 
[α]D20 –14.5 (c 0.2, CHCl3); IR 
(neat) 3403, 2951, 2928, 2835, 1713, 1687, 1593, 1517, 1463, 1265, 1248, 1159, 1080.9, 
1029 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.31 (ap s, 1 H), 7.27 (ap s, 1 H), 6.97 (d, J = 
8.4 Hz, 1 H), 6.93 (m, 2 H), 6.88 (d, J = 8.4 Hz, 1 H), 6.83 (d, J = 8.2 Hz, 1 H), 6.55 (s, 1 
H), 5.18 (dab, J = 12.0 Hz, 1 H), 5.11 (dab, J = 11.7 Hz, 1 H), 5.09 (d, J = 9.8 Hz, 1 H), 
4.98 (s, 2 H), 4.83 (dab, J = 6.4 Hz, 1 H), 4.81 (s, 1 H), 4.79 (s, 1 H), 4.73 (dab, J = 6.6 
Hz, 1 H), 4.65 (dab, J = 7.0 Hz, 1 H), 4.61 (dab, J = 7.0 Hz, 1 H), 4.38 (d, J = 2.0 Hz, 1 
H), 4.29-4.23 (m, 2 H), 3.99 (m, 1 H), 3.93 (s, 3 H), 3.90 (s, 3 H), 3.89 (s, 3 H), 3.88 (s, 3 
H), 3.75 (m, 1 H), 3.72 (m, 1 H), 3.56 (ddd, J = 6.4, 10.0, 10.0 Hz, 1 H), 3.51-3.42 (m, 2 
H), 3.40 (s, 3 H), 3.35 (aps, 1 H), 3.34 (s, 3 H), 3.21 (d, J = 15.9 Hz, 1 H), 2.68 (dd, J = 
12.7, 16.4 Hz, 1 H), 2.60 (dd, J = 11.4, 14.9 Hz, 1 H), 2.38 (dd, J = 8.9, 14.9 Hz, 1 H), 
2.27 (dd, J = 3.8, 10.9, 1 H), 2.24 (dd, J = 5.2, 12.3, 1 H), 2.14 (s, 3 H), 2.17 -2.09 (m, 1 
H), 1.86-1.75 (m, 2 H), 1.73 (s, 3 H), 1.25 (s, 3 H), 1.16 (d, J = 6.6 Hz, 3 H), 1.01 (s, 3 
H), 0.96-0.86 (m, 2 H), 0.82-0.76 (m, 1 H), 0.74-0.68 (m, 1 H), 0.01 (s, 9 H), –0.10 (s, 9 
H); 13C NMR (125 MHz, CDCl3) δ 210.8, 171.4, 163.7, 161.4, 160.4, 149.5, 149.4, 
149.3, 148.7, 142.2, 141.8, 129.5, 128.8, 120.3, 119.2, 116.1, 113.3, 111.2, 111.0, 110.9, 
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110.7, 108.0, 97.8, 95.0, 94.8, 81.7, 81.4, 79.8, 79.2, 77.6, 74.6, 72.8, 71.1, 70.5, 66.3, 
65.8, 58.1, 56.4, 56.2, 56.2, 56.1, 56.1, 49.6, 39.6, 38.8, 38.3, 30.2, 29.9, 24.8, 23.0, 19.5, 
18.2, 18.1, 11.4, 9.7, –1.2, –1.4; high resolution mass spectrum (ES+) m/z 1190.5880 
[(M+Na)+; calcd for C61H93NO17Si2Na: 1190.5880]. 
 
 
 
(–)-Irciniastatin B (2.2): To a solution of fully protected irciniastatin B (–)-2.57 (5.0 mg, 
0.0043 mmol) in CH2Cl2 (0.05 mL) and H2O (15 µL) was added a suspension of 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (0.1 mL, 0.33 M in CH2Cl2, 8 equiv). After 24 h, 
the reaction mixture was quenched with a saturated aq. solution of NaHCO3 and extracted 
with EtOAc (5 x 0.5 mL). The combined organic layers were dried over MgSO4, filtered 
and concentrated in vacuo. The crude mixture was purified via flash chromatography 
(40% EtOAc: hexanes) to afford a mixture (1:2) of desired bis-phenol and 3,4-
dimethoxybenzalehyde respectively. The mixture was treated with a stock solution of 
MgBr2/n-BuSH/MeNO2 in Et2O (0.21 mL: 25 equiv MgBr2, 25 equiv n-BuSH, stock 
solution made up of 75.4 mg MgBr2, 44 µL n-BuSH, 82 µL, MeNO2 and 0.82 mL Et2O). 
After 10 h, the reaction mixture was diluted with EtOAc, and quenched with a saturated 
aq. solution of NaHCO3 and extracted with EtOAc (5 x 0.5 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated in vacuo. The crude mixture was 
purified via flash chromatography with water washed SiO2 [50 g of SiO2 washed with 
H2O (500 mL) then MeOH (500 mL) then EtOAc (500 mL) then hexanes (500 mL) and 
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dried under vacuum overnight, then deactivated with 5% v/v triethylamine, 35% to 80% 
EtOAc: hexanes] to afford (–)-irciniastatin B (2.2) (2.0 mg, 0.0033 mmol, 78% over two 
steps) as a colorless solid: 
€ 
[α]D20 –28.7 (c 0.2, MeOH) [
€ 
[α]D20 –4.7 (c 0.15, MeOH) lit.]4 IR 
(neat) 3356, 2925, 2873, 1710, 1651, 1612, 1510, 1461, 1380, 1266, 1174, 1103 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 11.11 (s, 1 H), 7.37 (d, J = 10.4 Hz, 1 H), 6.64 (bs, 1 H), 6.30 
(s, 1 H), 5.20 (dd, J = 6.4 Hz, 10.1 Hz, 1 H), 4.82 (s, 1 H), 4.79 (s, 1 H), 4.55 (ddd, J = 
4.2, 4.2, 11.8 Hz, 1 H), 4.47 (ap t, J = 2.9 Hz, 1 H), 4.21 (ap q, J = 6.4 Hz, 1 H), 4.09 (d, 
J = 8.4 Hz, 1 H), 4.00 (dd, J = 1.8, 11.2 Hz, 1 H), 3.79-3.77 (m, 1 H), 3.77 (bs, 1H), 3.65 
(bs, 1 H), 3.39 (s, 3 H), 3.36 (s, 3 H), 2.94-2.83 (m, 2 H), 2.67 (ap d, J = 6.4 Hz, 2 H), 
2.36 (dd, J = 9.4, 14.5 Hz, 1 H), 2.14 (dd, J = 3.7, 14.5 Hz, 1 H), 2.04 (s, 3 H), 1.91 (1 H, 
m), 1.84 (ddd, J = 10.1, 14.6, 24.8 Hz, 1 H), 1.75 (s, 3 H), 1.59 (ap d, J = 14.0 Hz, 1 H), 
1.16 (s, 3 H), 1.11 (d, J = 7.2 Hz, 3 H), 1.10 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
210.3, 173.2, 170.7, 162.5, 161.3, 142.1, 139.9, 113.5, 113.3, 101.7, 101.5, 83.2, 80.5, 
80.5, 80.3, 73.8, 72.7, 72.4, 57.9, 56.6, 49.6, 42.8, 38.8, 37.4, 33.0, 28.3, 22.8, 22.3, 19.4, 
10.7, 9.2; HRMS (ES+) m/z 608.3058 [(M+1)+; calcd for C31H46NO11: 608.3071]. 
 
 
 
 
(+)-Irciniastatin A (2.1) and epi-C(11)-Irciniastatin A (2.60): To neat (–)-irciniastatin 
B (2.2) (1 mg, 1.6 µmol) was treated with a solution of NaBH4 (0.1 mL, 0.024 M in 
MeOH, 1.5 equiv) at 0 °C. After 15 min, the reaction mixture was quenched with a 
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saturated aq. solution of NaHCO3 (0.4 mL) and extracted with EtOAc (3 x 0.5 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The 
crude mixture (1:1) of (+)-2.1 and 2.60 was purified via preparatory TLC (70% EtOAc: 
hexanes, 250 micron SiO2 plate) to provide (+)-irciniastatin A (2.1) (0.3 mg, 0.5 µmol 
31%) and epi-C(11)-irciniastatin A (2.60) (0.3 mg, 0.5 µmol, 31%). 
Characterization data for (+)-irciniastatin A (2.1): 1H NMR (500 MHz, MeOD) δ 6.24 (s, 
1 H), 5.39 (d, J = 8.3 Hz, 1 H), 4.74 (s, 1 H), 4.71 (s, 1 H), 4.51-4.47 (ddd, J = 3.0, 5.9, 
12.0 Hz, 1 H), 4.35 (d, J = 2.6 Hz, 1 H), 3.94 (m, 2 H), 3.67 (ddd, J = 2.6, 3.5, 9.5 Hz, 1 
H), 3.60 (dd, J = 4.4, 10.9 Hz, 1 H), 3.50 (dd, J = 2.0, 10.1 Hz, 1 H), 3.35 (s, 3 H), 3.23 
(s, 3 H), 3.13 (dd, J = 3.3, 16.7 Hz, 1 H), 2.86 (dd, J = 12.0, 16.6 Hz, 1 H), 2.35 (dd, J = 
9.4, 14.8 Hz, 1 H), 2.11 (m, 1 H), 2.10 (s, 3 H), 2.02 (ddd, J = 2.6, 4.5, 13.4 Hz, 1 H), 
1.91 (m, 1 H), 1.86-1.74 (m, 2 H), 1.72 (s, 3 H), 1.68 (ddd, J = 2.1, 3.8, 14.6 Hz, 1 H), 
1.10 (d, J = 7.1 Hz, 3 H), 0.97 (s, 3 H), 0.90 (s, 3 H); 13C NMR (125 MHz, CDCl3) 
Observable peaks δ 176.3, 172.5, 163.9, 144.0, 141.2, 115.5, 113.1, 101.6, 82.8, 82.3, 
82.1, 79.9, 73.6, 73.3, 72.1, 57.8 56.7, 43.4, 39.9, 38.8, 34.5, 30.6, 29.6, 23.8, 23.0, 14.0, 
11.0, 9.3; HRMS (ES+) m/z 632.3033 [(M+Na)+; calcd for C31H47NO11Na: 632.3047]. 
Characterization data for epi-C(11)-irciniastatin A (2.60): 1H NMR (500 MHz, MeOD) 
Observable peaks δ 6.25 (s, 1 H), 5.25 (d, J = 3.6 Hz, 1 H), 4.76 (s, 1 H), 4.73 (s, 1 H), 
4.51-4.47 (ddd, J = 3.1, 6.8, 12.2 Hz, 1 H), 4.37 (d, J = 2.8 Hz, 1 H), 4.04 (m, 1 H), 3.97 
(dd, J = 4.0, 13.2 Hz, 1 H), 3.78 (dd, J = 3.1, 11.8 Hz, 1 H), 3.73-3.67 (m, 2 H), 3.33 (s, 3 
H), 3.17 (dd, J = 3.3, 16.7 Hz, 1 H), 2.83 (dd, J = 11.9, 16.2 Hz, 1 H), 2.35 (dd, J = 9.7, 
15.0 Hz, 1 H), 2.12 (dd, J = 3.9, 14.2 Hz, 1 H), 2.09 (s, 3 H), 1.96 (m, 2 H), 1.79 (m, 1 
H), 1.73 (s, 3 H), 1.63 (m, 2 H), 1.12 (d, J = 7.0 Hz, 3 H), 1.01 (s, 3 H), 0.93 (s, 3 H); 13C 
!94!
NMR (125 MHz, CDCl3) Observable peaks δ 176.0, 172.6, 164.7, 163.8, 144.0, 141.2, 
115.4, 113.2, 101.5, 101.5, 83.0, 82.5, 73.0, 72.7, 72.0, 57.9, 56.7, 42.8, 39.0, 38.7, 30.9, 
29.6, 23.1, 22.8, 21.3, 10.9, 9.7; HRMS (ES+) m/z 632.3029 [(M+Na)+; calcd for 
C31H47NO11Na: 632.3047].  
!
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Acetate (+)-S2: To a solution of alcohol (–)-3.4 (7.0 mg, 0.006 mmol) in pyridine (0.42 
mL) was added acetic anhydride (0.18 mL) dropwise. The reaction mixture was stirred 
for 7.5 h at rt. Reaction was quenched with a saturated aq. solution of NaHCO3 and 
extracted with EtOAc (3 x 0.5 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude mixture was purified via flash 
chromatography on SiO2 (40% to 45% EtOAc: hexanes) to furnish acetate (+)-S2 (6.3 
mg, 0.0051 mmol, 87%) as a colorless oil: 
€ 
[α]D20 +5.3 (c 0.5, CHCl3); IR (neat) 3391, 
2925, 2858, 1716, 1687, 1592, 1516, 1462, 1371, 1249, 1150 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 7.31 (ap s, 1 H), 7.23 (d, J = 9.7 Hz, 1 H), 6.98 -6.92 (m, 3 H), 6.87 (d, J = 8.7 
Hz, 1 H), 6.83 (d, J = 8.0 Hz, 1 H), 6.54 (s, 1 H), 5.16 (dab, J = 11.5 Hz, 1 H), 5.10 (dab, 
J = 12.3 Hz, 1 H), 5.07 (d, J = 10.6 Hz, 1 H), 4.98 (s, 2 H), 4.87 (ap t, J = 3.9 Hz, 1 H), 
4.82 (d, J = 6.8 Hz, 1 H), 4.78 (s, 1 H), 4.77 (s, 1 H), 4.71 (ap t, J = 7.6 Hz, 2 H), 4.63 (d, 
J = 7.2 Hz, 1 H), 4.38 (ap s, 1 H), 4.31 (m, 1 H), 4.00 (dd, J = 2.9, 9.6 Hz, 2 H), 3.92 (s, 3 
H), 3.90 (s, 3 H), 3.88 (s, 3 H), 3.87 (s, 3 H), 3.76 -3.71 (m, 2 H), 3.58 (dd, J = 6.9, 10.0 
Hz, 1 H), 3.56-3.49 (m, 2 H), 3.49-3.44 (m, 1 H), 3.37 (s, 3 H), 3.31 (s, 3 H), 3.23 (d, J = 
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15.4 Hz, 1 H), 2.67 (dd, J = 12.8, 16.4 Hz, 1 H), 2.36 (dd, J = 8.8, 14.6 Hz, 2 H), 2.20 
(dd, J = 4.3, 14.5 Hz, 1 H), 2.14 (s, 3 H), 2.11 (m, 1 H), 2.08 (s, 3 H), 1.83-1.74 (m, 2 H), 
1.71 (s, 3 H), 1.57 (ddd, J = 4.1, 7.9, 18.2 Hz, 1 H), 1.16 (d, J = 6.8 Hz, 3 H), 1.05 (s, 3 
H), 0.95-0.90 (m 1 H), 0.88 (s, 3 H), 0.86-0.84 (m, 1 H), 0.86-0.79 (ddd, J = 5.9, 11.5, 
17.5 Hz, 1 H), 0.74-0.69 (ddd, J = 5.9, 11.7, 17.7 Hz, 1 H), 0.01 (s, 9 H), –0.11 (s, 9 H); 
13C NMR (125 MHz, CDCl3) δ 171.2, 170.3, 163.7, 161.3, 160.4, 149.6, 149.4, 149.3, 
148.8, 142.4, 142.1, 129.6, 128.9, 120.2, 119.2, 116.2, 113.0, 111.3, 111.1, 111.0, 110.8, 
108.1, 97.9, 94.8, 94.4, 81.7, 81.5, 79.3, 75.6, 74.5, 71.2, 70.5, 66.2, 65.7, 58.0, 56.4, 
56.2, 56.1, 56.1, 39.3, 38.4, 36.4, 30.2, 30.0, 29.9, 29.6, 27.9, 26.1, 22.9, 21.4, 20.2, 18.2, 
18.2, 11.4, 9.7, –1.2, –1.4; high resolution mass spectrum (ES+) m/z 1212.6318 [(M+H)+; 
calcd for C63H98NO18Si2: 1212.6322]. 
 
!
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C(11)-OAc-Irciniastatin A (+)-3.7: To a solution of fully protected acetate (+)-S2 (5.1 
mg, 0.0042 mmol) in CH2Cl2 (50 µL) and H2O (15 µL) was added a suspension of 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (0.1 mL, 0.33 M in CH2Cl2, 8 equiv). After 10 h, 
the reaction mixture was quenched with a saturated aq. solution of NaHCO3 and extracted 
with EtOAc (5 x 0.5 mL). The combined organic layers were dried over MgSO4, filtered 
and concentrated in vacuo. The crude mixture was purified via flash chromatography on 
SiO2 (50% EtOAc: hexanes) to afford a mixture (1:2) of the desired bis-phenol and 3,4-
dimethoxybenzalehyde respectively. The mixture was treated with a stock solution of 
MgBr2/n-BuSH/MeNO2 in Et2O (0.155 mL: 25 equiv MgBr2, 25 equiv n-BuSH, stock 
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solution made up of 57.4 mg MgBr2, 33 µL n-BuSH, 62 µL, MeNO2 and 0.62 mL Et2O). 
After 9 h, the reaction mixture was diluted with EtOAc, and quenched with a saturated 
aq. solution of NaHCO3 and extracted with EtOAc (5 x 0.5 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated in vacuo. The crude mixture was 
purified via flash chromatography on SiO2 [deactivated with 5% v/v triethylamine, 40% 
to 80% EtOAc: hexanes] to afford (+)-C(11)-OAc-irciniastatin A (+)-3.7 (1.9 mg, 0.0031 
mmol, 75% over two steps) as a colorless solid:  +3.9 (c 0.15, CHCl3); IR (neat) 
3372, 2923, 2850, 1737, 1661, 1617, 1515, 1461, 1373, 1251, 1172, 1108, 1071 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 11.15 (s, 1 H), 7.17 (d, J = 9.7 Hz, 1 H), 6.59 (bs, 1 H), 6.30 
(s, 1 H), 5.43 (dd, J = 1.6, 10.3 Hz, 1 H), 4.89 (dd, J = 4.4, 9.3 Hz, 1 H), 4.81 (s, 1 H), 
4.80 (s, 1 H), 4.59 (ddd, J = 3.8, 8.3, 11.8 Hz, 1 H), 4.43 (app bs, 1 H), 4.24 (app bs, 1 
H), 3.97-3.90 (m, 2 H), 3.77-3.74 (m, 2 H), 3.65 (d, J = 10.5 Hz, 1 H), 3.44-3.35 (m, 1H), 
3.40 (s, 3 H), 3.39 (s, 3 H), 2.91-2.80 (m, 2 H), 2.37 (dd, J = 8.8, 14.6 Hz, 1 H), 2.18 (dd, 
J = 3.9, 14.8 Hz, 1 H), 2.10 (s, 3 H), 2.03 (s, 3 H), 1.91 (m, 2 H), 1.83-1.78 (m, 1 H), 1.76 
(s, 3 H), 1.63 (d, J = 15.0 Hz, 1 H), 1.11 (d, J = 7.1 Hz, 3 H), 0.97 (s, 3 H), 0.96 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 173.3, 170.7, 162.5, 161.1, 142.2, 140.0, 113.3, 113.3, 
101.9, 101.5, 82.6, 80.6, 79.4, 79.0, 74.0, 73.4, 72.8, 71.8, 58.0, 56.7, 56.1, 42.8, 37.6, 
37.5, 31.9, 29.9, 28.7, 27.1, 24.1, 22.9, 21.4, 10.7, 9.6; HRMS (ES+) m/z 674.3155 
[(M+Na)+; calcd for C33H49NO12Na: 674.3152]. 
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Benzoate (+)-S3: To a solution of alcohol (–)-3.4 (6.0 mg, 0.005 mmol) in pyridine (0.30 
mL) was added benzoyl chloride (30 µL, 0.43 mmol, 85 equiv) dropwise. The reaction 
mixture was stirred for 1 h at rt. Additional benzoyl chloride (50 µL) was then added 
reaction mixture was stirred for 30 min. The reaction mixture was quenched with a 
saturated aq. solution of NaHCO3 and extracted with EtOAc (3 x 0.5 mL). The combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo. The crude 
mixture was purified via flash chromatography on SiO2 (30% to 40% EtOAc: hexanes) to 
furnish benzoate (+)-S3 (3.6 mg, 0.003 mmol, 55%) as a colorless foam:  +12.8 (c 
0.3, CH2Cl2); IR (neat) 3454, 3351, 2954, 2926, 2855, 1729, 1438, 1251, 1157, 1101, 
1066, 1011, 1066, 833, 772 cm-1; 1H NMR (500 MHz, MeOD) δ 8.17-8.00 (m, 3 H), 7.59 
(t, J = 8.3 Hz, 1 H), 7.49 (t, J = 7.7 Hz, 2 H), 7.26 (s, 1 H), 7.08 (s, 1 H), 6.97 (d, J = 8.3 
Hz, 1 H), 6.94 (s, 2 H), 6.89 (d, J = 8.4 Hz, 1 H), 6.74 (s, 1 H), 5.22 (dd, J = 5.2, 5.7 Hz, 
1 H), 5.20 (dab, J = 12.7 Hz, 1 H), 5.16-5.14 (m, 1 H), 5.14 (dab, J = 12.7 Hz, 1 H), 5.09 
(ap s, 2 H), 4.76-4.68 (m, 6 H), 4.42 (ddd, J = 1.7, 5.4, 10.9 Hz, 1 H), 4.28 (d, J = 3.2 Hz, 
1 H), 4.04 (m, 1 H), 3.93 (m, 1 H), 3.84 (s, 3 H), 3.82 (s, 3 H), 3.82 (bs, 6 H), 3.70 (ddd, J 
= 6.5, 10.0, 10.0 Hz, 1 H), 3.63 (m, 2 H), 3.62-3.60 (m, 3 H), 3.38 (s, 3 H), 3.24 (s, 3 H), 
2.79 (dd, J = 12.6, 16.6 Hz, 1 H), 2.30 (dd, J = 9.0, 14.7 Hz, 1 H), 2.20 (d, J = 3.4 Hz, 1 
H), 2.17 (s, 3 H), 2.14 (dd, J = 4.5, 8.3 Hz, 1 H), 2.11 (dd, J = 2.9, 6.5 Hz, 1 H), 1.99 (m, 
1 H), 1.90-1.85 (m, 1 H), 1.69 (s, 3 H), 1.15 (d, J = 6.8 Hz, 3 H), 1.11 (s, 3 H), 1.05 (s, 3 
H), 0.88-0.78 (m, 3 H), 0.68 (ddd, J = 5.6, 11.4, 13.4 Hz, 1 H), –0.04 (s, 9 H), –0.13 (s, 9 
H); 13C NMR (125 MHz, CD3OD) δ 173.9, 173.8, 167.5, 166.4, 163.3, 162.1, 150.8, 
150.8, 150.7, 150.2, 143.8, 143.4, 136.1, 134.6, 133.9, 131.7, 131.6, 131.2, 130.8, 130.7, 
130.4, 129.6, 121.6, 120.9, 117.2, 113.5, 113.0, 112.8, 112.7, 112.4, 107.8, 99.1, 96.0, 
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95.5, 83.0, 82.9, 82.7, 80.7, 78.5, 78.5, 78.3, 76.7, 71.7, 71.5, 67.1, 66.8, 58.5, 57.0, 56.6, 
56.6, 40.7, 39.7, 38.4, 32.4, 31.3, 28.2, 25.6, 23.2, 19.1, 19.1, 11.8, 9.4, –1.1, –1.3; high 
resolution mass spectrum (ES+) m/z 1296.6295 [(M+Na)+; calcd for C68H99NO18Si2Na: 
1296.6298]. 
 
 
 
C(11)-OBz-Irciniastatin A (–)-3.6: To a solution of fully protected benzoate (+)-S3 (3.6 
mg, 0.0028 mmol) in CH2Cl2 (100 µL) and H2O (18 µL) was added a suspension of 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (80 µL, 0.29 M in CH2Cl2, 8 equiv). After 10 h, 
the reaction mixture was quenched with a saturated aq. solution of NaHCO3 and extracted 
with EtOAc (5 x 0.5 mL). The combined organic layers were dried over MgSO4, filtered 
and concentrated in vacuo. The crude mixture was purified via flash chromatography on 
SiO2 (50% EtOAc: hexanes) to afford a mixture (1:2) of the desired bis-phenol and 3,4-
dimethoxybenzalehyde respectively. The mixture was treated with a stock solution of 
MgBr2/n-BuSH/MeNO2 in Et2O (0.140 mL: 25 equiv MgBr2, 25 equiv n-BuSH, stock 
solution made up of 89.9 mg MgBr2, 36 µL n-BuSH, 100 µL, MeNO2 and 0.98 mL 
Et2O). After 9.5 h, the reaction mixture was diluted with EtOAc, and quenched with a 
saturated aq. solution of NaHCO3 and extracted with EtOAc (5 x 0.5 mL). The combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo. The crude 
mixture was purified via flash chromatography on SiO2 (40% to 50% EtOAc: hexanes) to 
afford (+)-C(11)-OBz-irciniastatin A (–)-3.6 (1.0 mg, 0.0014 mmol, 50% over two steps) 
O
N
H
OMeO
OH
OMe
H
OHO
O
HO
OH
H
OBz
!99!
as a colorless solid:  –13.7 (c 0.08, CHCl3); IR (neat) 3372, 2943, 1726, 1663, 1599, 
1446, 1377, 1253, 1114 cm-1; 1H NMR (500 MHz, C6D6) δ 11.93 (bs, 1 H), 8.17 (d, J = 
7.5 Hz, 3 H), 7.10 (t, J = 7.5 Hz, 2 H), 6.31 (s, 1 H), 5.67 (t, J = 8.3 Hz, 1 H), 5.27 (dd, J 
= 4.4, 9.9 Hz, 1 H), 5.04 (s, 1 H), 4.92 (s, 1 H), 4.61 (bs, 1 H), 4.33 (m, 3 H), 4.17 (d, J = 
9.7 Hz, 1 H), 3.91 (ddd, J = 3.5, 3.5, 4.0 Hz, 1 H), 3.73 (d, J = 10.4 Hz, 1 H), 3.59 (bs, 1 
H), 3.32 (s, 3 H), 3.25 (s, 3 H), 2.63 (d, J = 16.3 Hz, 1 H), 2.65-2.51 (ddd, J = 8.7, 12.4, 
12.4 Hz, 1 H), 2.46 (dd, J = 4.6, 14.0 Hz, 2 H), 2.26 (m, 1  H), 2.02 (s, 3 H), 1.93 (m, 1 
H), 1.79 (s, 3 H), 1.58 (bs, 1 H), 1.46 (d, J = 13.9 Hz, 1 H), 1.06 (d, J = 6.6 Hz, 3 H), 0.96 
(s, 3 H), 0.79 (s, 3 H); 13C NMR (125 MHz, C6D6) δ 173.7, 170.9, 165.7, 163.2, 161.8, 
142.6, 140.1, 133.2, 130.9, 129.9, 128.8, 127.5, 113.6, 113.5, 102.0, 101.6, 82.2, 81.5, 
80.1, 78.9, 74.3, 73.8, 73.5, 57.8, 56.3, 43.1, 38.1, 37.8, 33.0, 32.4, 30.2, 30.1, 28.4, 27.2, 
23.1, 14.4, 10.6, 9.2; HRMS (ES+) m/z 736.3286 [(M+Na)+; calcd for C38H51NO12Na: 
736.3309]. 
 
  
 
Fluoride (+)-S4: To a solution of alcohol (+)-3.4 (4.0 mg, 0.003 mmol) in CH2Cl2 (0.15 
mL) was added DAST (0.05 mL, 0.2 M in CH2Cl2, 4 equiv) dropwise. The reaction 
mixture was stirred for 15 min at rt. The reaction was quenched with a saturated aq. 
solution of NaHCO3 and extracted with EtOAc (3 x 0.5 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated in vacuo. The crude mixture was 
purified via flash chromatography on SiO2 (35% to 40% to 45% EtOAc: hexanes) to 
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furnish fluoride (+)-S4 (2.6 mg, 0.0022 mmol, 65%) as a colorless oil: 
€ 
[α]D20 +5.6 (c 0.3, 
CHCl3); IR (neat) 3428, 2921, 2851, 1715, 1683, 1592, 1516, 1462, 1247, 1158, 1083 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.33 (d, J = 1.9 Hz, 1 H), 7.01-6.92 (m, 4 H), 6.88 
(d, J = 8.0 Hz, 1 H), 6.84 (d, J = 8.2 Hz, 1 H), 6.54 (s, 1 H), 5.16 (dab, J = 11.4 Hz, 1 H), 
5.09 (dab, J = 11.8 Hz, 1 H), 5.07 (dd, J = 3.1, 10.0 Hz, 1 H), 4.99 (s, 2 H), 4.82 (m, 1 
H), 4.80 (m, 1 H), 4.71 (d, J = 6.3 Hz, 1 H), 4.68 (d, J = 7.1 Hz, 1 H), 4.60 (d, J = 7.1 Hz, 
1 H), 4.36 (d, J = 2.3 Hz, 1 H), 4.29 (ddd, J = 2.3, 7.5, 12.0 Hz, 1 H), 4.22-4.18 (ddd, J = 
4.9, 5.8, 10.3 Hz, 1 H), 4.16-4.12 (ddd, J = 3.2, 4.6, 9.4 Hz, 1 H), 3.97-3.94 (m, 1 H), 
3.93 (s, 3 H), 3.90 (s, 3 H), 3.89 (s, 3 H) 3.88 (s, 3 H), 3.78-3.70 (m, 2 H), 3.61-3.56 
(ddd, J = 6.9, 9.8, 19.9 Hz, 1 H), 3.52-3.43 (m, 2 H), 3.40 (s, 3 H), 3.33 (s, 3 H), 3.19 (dd, 
J = 2.4, 16.3 Hz, 1 H), 2.70 (dd, J = 11.8, 16.1 Hz, 1 H), 2.37 (dd, J = 8.6, 14.6 Hz, 1 H), 
2.33-2.25 (ddd, J = 3.1, 8.7, 18.3 Hz, 1 H), 2.23 (dd, J = 4.7, 14.3 Hz, 1 H), 2.14 (s, 3 H), 
2.13-2.10 (m, 2 H), 1.89 (m, 2 H), 1.83 (ddd, J = 4.5, 8.3, 12.9 Hz, 1 H), 1.75 (s, 3 H), 
1.40 (d, J = 15.1 Hz, 3 H), 1.36 (d, J = 15.8 Hz, 3 H), 1.17 (d, J = 6.8 Hz, 3 H), 1.02-0.84 
(m, 2 H), 0.84-0.78 (ddd, J = 6.4, 11.2, 13.9 Hz, 1 H), 0.73-0.67 (ddd, J = 6.1, 11.0, 13.6 
Hz, 1 H), 0.01 (s, 9 H), –0.10 (s, 9 H); 19F NMR (470 MHz, CDCl3) δ 147.4; 13C NMR 
(125 MHz, CDCl3) δ 171.3, 163.6, 161.3, 160.5, 149.6, 149.5, 149.4, 148.9, 142.4, 142.0, 
129.7, 129.0, 120.3, 119.2, 116.3, 113.1, 111.4, 111.2, 111.1, 110.9, 108.2, 98.1, 95.0, 
94.4 (d, J = 171.0 Hz), 94.5 82.1, 81.5, 78.9, 77.9, 77.4, 76.1, 71.3, 70.6, 66.4, 65.8, 58.1, 
56.4, 56.3, 56.2, 56.2, 51.3 (d, J = 21.2 Hz), 40.2, 38.4, 32.0 (d, J = 5.1 Hz), 30.1, 29.9, 
27.7, 27.6, 27.5 (d, J = 25.6 Hz), 27.0 (d, 24.6 Hz), 23.0, 18.3, 18.2, 11.4, 10.1, –1.2, –
1.4; high resolution mass spectrum (ES+) m/z 1172.6189 [(M+H)+; calcd for 
C61H95NO16Si2F: 1172.6173]. 
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Olefin (–)-S5: To a solution of Ph3MeBr (75.4 mg, 0.211 mmol) in THF (0.46 mL) was 
added KOt-Bu (0.20 mL, 0.20 mmol) to provide a yellow solution, which was stirred for 
5 minutes. The ylide solution (40 µL, 0.32 M in THF, 2.5 equiv) was added to a separate 
vial containing a solution of ketone (–)-3.5 (6.0 mg, 0.0051 mmol) in THF (0.26 mL) and 
the yellow reaction mixture was allowed to stir for 1 h at rt. The reaction mixture was 
quenched with water and extracted with EtOAc (4 x 0.5 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated in vacuo. The crude mixture was 
purified via flash chromatography on SiO2 (40% EtOAc: hexanes) to furnish olefin (–)-
S5 (5.0 mg, 0.0043 mmol, 84%) as a colorless oil: 
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[α]D20 –3.4 (c 0.4, CHCl3); IR (neat) 
3422, 2951, 1715, 1686, 1592, 1515, 1463, 1417, 1378, 1246, 1157, 1083, 1027 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.41 (d, J = 9.7 Hz, 1 H), 7.31 (ap s, 1 H), 6.97-6.93 (m, 3 H), 
6.87 (d, J = 8.5 Hz, 1 H), 6.88 (d, J = 8.3 Hz, 1 H), 6.54 (s, 1 H), 5.17 (dab, J = 11.7 Hz, 
1 H), 5.10 (dab, J = 11.7 Hz, 1 H), 5.03 (d, J = 19.9 Hz, 1 H), 4.98 (s, 2 H), 4.87 (d, J = 
5.5 Hz, 1 H), 4.86 (s, 1 H), 4.78 (ap s, 2 H), 4.70 (d, J = 13.6 Hz, 1 H), 4.64 (dab, J = 7.0 
Hz, 1 H), 4.60 (dab, J = 6.8 Hz, 1 H), 4.42 (ap s, 1 H), 4.22 (ap t, J = 10.8 Hz, 1 H), 3.96 
(m, 2 H), 3.92 (s, 3 H), 3.90 (s, 3 H), 3.88 (s, 3 H), 3.87 (s, 3 H), 3.80-3.74 (m, 2 H), 3.58 
(ddd, J = 64, 9.7, 9.7 Hz, 1 H), 3.53-3.48 (m, 2 H), 3.42 (dd, J = 5.3, 11.0 Hz, 1 H), 3.40 
(s, 3 H), 3.30 (s, 3 H), 3.23 (d, J = 16.1 Hz, 1 H), 2.64 (dd, J = 12.3, 16.2 Hz, 1 H), 2.38 
(dd, J = 9.0, 14.9 Hz, 1 H), 2.30-2.22 (m, 2 H), 2.13 (s, 3 H), 2.06-1.97 (m, 2 H), 1.72 (s, 
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3 H), 1.66-1.63 (m, 1 H), 1.19 (s, 3 H), 1.16 (d, J = 6.7 Hz, 3 H), 0.99 (s, 3 H), 0.95-0.86 
(m, 2 H), 0.84-0.78 (ddd, J = 5.6, 12.0, 14.0 Hz, 1 H), 0.75-0.67 (ddd, J = 6.1, 12.2, 13.8 
Hz, 1 H), 0.01 (s, 9 H), –0.10 (s, 9 H); 13C NMR (125 MHz, CDCl3) δ171.5, 163.8, 161.3, 
160.4, 149.6, 149.4, 149.3, 148.8, 148.3, 142.4, 142.1, 129.6, 128.9, 120.2, 119.2, 116.1, 
113.0, 111.3, 111.1, 111.0, 110.8, 109.7, 108.2, 97.9, 94.9, 94.7, 81.6, 81.5, 79.7, 79.4, 
74.6, 72.2, 71.2, 70.5, 66.1, 65.5, 58.1, 56.3, 56.2, 40.2, 39.5, 38.4, 33.8, 29.9, 28.7, 27.5, 
23.2, 23.0, 18.2, 11.4, 9.6, –1.2, –1.4; high resolution mass spectrum (ES+) m/z 
1188.6088 [(M+Na)+; calcd for C62H95NO16Si2Na: 1188.6087]. 
 
 
 
C(11)-Exomethylene-Irciniastatin B (+)-3.9: To a solution of olefin (–)-S6 (5.0 mg, 
0.0043 mmol) in CH2Cl2 (0.05 mL) and H2O (15 µL) was added a suspension of 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (0.1 mL, 0.34 M in CH2Cl2, 8 equiv). After 11.5 
h, the reaction mixture was quenched with a saturated aq. solution of NaHCO3 and 
extracted with EtOAc (5 x 0.5 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude mixture was purified via flash 
chromatography (50% EtOAc: hexanes) to afford a mixture (1:2) of desired bis-phenol 
and 3,4-dimethoxybenzalehyde respectively. The mixture was treated with a stock 
solution of MgBr2/n-BuSH/MeNO2 in Et2O (0.200 mL: 25 equiv MgBr2, 25 equiv n-
BuSH, stock solution made up of 42.3 mg MgBr2, 18 µL n-BuSH, 46 µL, MeNO2 and 
0.46 mL Et2O). After 10 h, the reaction mixture was diluted with EtOAc, and quenched 
with a saturated aq. solution of NaHCO3 and extracted with EtOAc (5 x 0.5 mL). The 
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combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The 
crude mixture was purified via flash chromatography with SiO2 [deactivated with 5% v/v 
triethylamine, 40% to 80% EtOAc: hexanes] to afford (+)-C(11)-exomethylene-
irciniastatin A (+)-3.9 (2.0 mg, 0.0033 mmol, 77% over two steps) as a colorless solid: 
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[α]D20 +12.7 (c 0.17, CHCl3); IR (neat) 3379, 2921, 1732, 1659, 1623, 1514, 1454, 1379, 
1254, 1109 cm-1; 1H NMR (500 MHz, CDCl3) δ 11.15 (s, 1 H), 7.28 (d, J = 6.7, 10.3 Hz, 
1 H), 6.68 (bs, 1 H), 6.30 (s, 1 H), 5.28 (dd, J = 6.7, 10.3 Hz, 1 H), 4.87 (s, 2 H), 4.81 (s, 
1 H), 4.79 (s, 1 H), 4.52 (ddd, J = 4.0, 8.0, 16.4 Hz, 1 H), 4.45 (d, J = 3.0 Hz, 1 H), 4.01 
(d, J = 10.1 Hz, 1 H), 3.92-3.88 (m, 2 H), 3.77-3.74 (ddd, J = 3.8, 9.4, 12.7 Hz, 1 H), 3.63 
(d, J = 10.7 Hz, 1 H), 3.40 ( s, 3 H), 3.35 (s, 3 H), 3.34-3.31 (m, 1 H), 2.93-2.80 (m, 2 H), 
2.52 (dd, J = 5.4, 14.2 Hz, 1 H), 2.42-2.35 (m, 2 H), 2.16 (dd, J = 3.9, 14.8 Hz, 1 H), 2.02 
(s, 3 H), 1.88 (m, 1 H), 1.79 (dd, J = 2.8, 10.6 Hz, 1 H), 1.75 (3 H, s), 1.55 (d, J = 14.5 
Hz, 1 H), 1.14 (s, 3 H), 1.10 (d, J = 7.0 Hz, 3 H), 1.06 (s, 3 H); 13C NMR (125 MHz, 
CDCl3) δ 173.3, 170.7, 162.5, 161.2, 148.2, 142.2, 140.0, 113.4, 113.2, 110.0, 101.7, 
101.5, 83.4, 80.6, 80.2, 79.1, 73.9, 73.2, 72.7, 58.0, 56.5, 43.0, 39.9, 37.5, 33.0, 32.1, 
28.5, 25.0, 22.9, 21.7, 10.7, 9.5; HRMS (ES—) m/z 606.3280 [(M–H)–; calcd for 
C32H48NO10: 606.3278]. 
 
 
 
Allylic Alcohol 3.15: To a solution of alkene S65 (232.9 mg, 1.09 mmol) in THF was 
added methyl acrylate (0.30 mL, 3.26 mmol, 3.0 equiv), followed by Grubbs-Hoveyda 
second-generation catalyst (17.8 mg, 0.027 mmol, 0.025 equiv). The reaction mixture 
TBSO
i. Methyl Acrylate
  Grubbs-Hoveyda 2nd Generation Catalyst
  CH2Cl2, reflux
ii. DIBAL-H, –78 °C to 0 °C
TBSO OH
S6 3.15
60%, E/Z ratio: > 20:1
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was warmed to reflux and stirred for 2.5 h. The reaction mixture was then cooled to –78 
°C and added DIBAL-H (7.6 mL, 1 M in THF, 7 equiv). After 1 h, the reaction mixture 
was warmed to 0 °C and stirred at this temperature for 30 min and quenched with MeOH. 
The reaction mixture was warmed to rt and diluted with EtOAc and added saturated 
solution of Rochelle’s salt. The mixture was stirred for 1 h in which the reaction mixture 
became a homogenous solution. The layers were separated and the aqueous layer was 
extracted with EtOAc (3 x 15 mL). The combined organic layers were dried over MgSO4, 
filtered and concentrated in vacuo. The crude mixture was purified via flash 
chromatography on SiO2 (10% to 20% EtOAc: hexanes) to provide allylic alcohol 3.15 
(159.0 mg, 0.65 mmol, 60% yield) as a yellow oil (E/Z ratio > 20:1). Spectral data of 3.15 
was in complete agreement with spectral data presented in the literature:6 1H NMR (500 
MHz, CDCl3) δ 5.70-5.58 (m, 2 H), 4.06 (d, J = 5.5 Hz, 2 H), 3.59 (t, J = 6.3 Hz, 2 H), 
2.04 (dt, J = 7.3, 6.7 Hz, 2 H), 1.76 (bs, 1 H), 1.54-1.48 (m, 2 H), 1.44-1.38 (m, 2 H), 
0.87 (s, 9 H), 0.028 (s, 6 H); 13C NMR (125 MHz, CDCl3) δ 133.3, 129.3, 63.9, 63.2, 
32.5, 32.1, 26.1, 25.5, 18.5, 5.1. 
 
Epoxy Ester 3.17: To freshly activated 4 Å molecular sieves (2.0 g, beads) was added (–
)-DIPT (0.27 mL, 0.15 equiv). The solution was cooled to –20 °C and Ti(Oi-Pr)4 (0.23 
mL, 0.10 equiv) was added followed by t-BuOOH (3.30 mL, 5 M in decane, 2.0 equiv). 
The reaction was stirred for 30 min and then allylic alcohol 3.15 (2.012 g, 8.24 mol) 
dissolved in CH2Cl2 (50 ml) was added via addition funnel. After 3 h, aq. citric acid 
solution (1.0 M) was added and the reaction was warmed to rt.  After 1 h at rt, the layers 
were separated, and the aqueous layer was extracted with CH2Cl2 (3 x 25 mL).  The 
TBSO OMe
O O
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combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The 
crude mixture was purified via flash chromatography on SiO2 (10% to 15% to 20% 
EtOAc: hexanes) to provide epoxide 3.16 [1.986 g, contaminated with (–)-DIPT] as a 
yellow oil. 
To a solution of epoxide 3.16 containing (–)-DIPT contaminant (1.986 g total mass, ~6.5 
mol of 3.16) in CH2Cl2 (65 mL) and DMSO (4.6 mL, 65 mol, 10 equiv) at 0 °C was 
added i-Pr2NEt (5.7 mL, 32.5 mol, 5 equiv) followed by SO3•pyridine (5.21 g, 32.5 mol, 
5 equiv) in one portion. After 30 min, aqueous saturated NaHCO3 solution (50 mL) was 
added and the layers were separated. The aqueous layer was extracted with CH2Cl2 (3 x 
50 mL) and the combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuo. The unpurified aldehyde was used in the step without further 
purification. 
The unpurified aldehyde was dissolved in t-BuOH (70 mL) and pH 7 buffer (24 mL).  
The solution was cooled to 0 °C, followed by addition of 2-methyl-2-butene (7.1 mL), 
NaH2PO4•H2O (5.12 g, 32.5, 5 equiv), and NaClO2 (3.70 g, 80 wt%, 32.5 mol, 5 equiv).  
After 2 h, the reaction was quenched with brine and extracted with EtOAc (5 x 100 mL).  
The combined organic layers were dried over MgSO4 and concentrated.  The unpurified 
acid was used in the next step without further purification. 
The unpurified acid was dissolved in CH2Cl2 (32.5 mL) and the solution was cooled to 0 
°C, followed by dropwise addition of TMS-diazomethane (4.2 mL, 2.0 M in Et2O, 1.3 
equiv) until the solution remained yellow in color. Glacial acetic acid was added 
dropwise until bubbling stopped to quench the excess TMS-diazomethane. The reaction 
!106!
mixture was concentrated in vacuo and the crude oil obtained was purified via flash 
chromatography on SiO2 (5% EtOAc: hexanes) to provide ester (+)-3.17 (1.4076 g, 4.88 
mol, 59% yield, 4 steps) as a colorless oil: [α]20D   +13.7 (c 2.23, CH2Cl2); IR (neat) 2932, 
2858, 1757, 1446, 1389, 1359, 1290, 1253, 1204, 1100, 837, 777 cm-1; 1H NMR (500 
MHz, CDCl3) δ 3.77 (s, 3 H), 3.61 (t, J = 5.9 Hz, 2 H), 3.23 (d, J = 1.9 Hz, 1 H), 3.17-
3.15 (ddd, J = 1.9, 4.8, 6.2 Hz, 1 H), 1.71-1.64 (m, 2 H), 1.62-1.48 (m, 4 H), 0.88 (s, 9 
H), 0.04 (s, 6 H); 13C NMR (125 MHz, CDCl3) δ 170.0, 62.9, 58.7, 53.2, 52.6, 32.5, 31.4, 
26.1, 22.4, 18.5, –5.1; high resolution mass spectrum (ES+) m/z 311.1659 [(M+Na)+; 
calcd for C14H28O4SiNa: 311.1655]. 
 
Alcohol (+)-3.18: A solution of HFPy. [2.7 M in THF, 3.9 mL, 10 equiv; stock solution 
made up of 0.4 mL HFPy, 0.8 mL pyridine, 4.0 mL THF] was added to neat TBS ether 
(+)-3.17 (295.4 mg, 1.03 mmol). The reaction mixture was stirred at rt for 5 h before 
quenching with saturated solution of NaHCO3. The layers were separated and the 
aqueous layer was extracted with EtOAc (3 x 20 mL). The combined organic layers were 
dried over MgSO4, filtered, and concentrated in vacuo. The crude oil was purified via 
flash chromatography on SiO2 (40% to 60% EtOAc: hexanes) to afford alcohol (+)-3.18 
(148.3 mg, 0.85 mmol, 82%) as a colorless oil:  +20.4 (c 0.8, CH2Cl2); IR (neat) 
3394, 2942, 2863, 1743, 1447, 1293, 1250, 1208, 1022 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 3.77 (s, 3H), 3.61 (t, J = 6.0 Hz, 2 H), 3.24 (d, J = 1.9 Hz, 1 H), 3.17 (ddd, J = 
1.9, 4.7, 5.7 Hz, 1 H), 1.75-1.67 (m, 1 H), 1.66-1.60 (m, 3 H), 1.59-1.52 (m, 2 H); 13C 
€ 
[α]D20
HO OMeO
O
!107!
NMR (125 MHz, CDCl3) δ 169.9, 62.7, 58.6, 53.1, 52.7, 32.4, 31.4, 22.3; HRMS (ES+) 
m/z 197.0799 [(M+Na)+; calcd for C8H14O4: 197.0790]. 
!108!
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